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A B S T R A C T
Background
This is an updated version of the original Cochrane review published in Issue 1, 2010, on ’Benzodiazepines for the relief of breathlessness
in advanced malignant and non-malignant diseases in adults’. Breathlessness is one of the most common symptoms experienced in the
advanced stages of malignant and non-malignant disease. Benzodiazepines are widely used for the relief of breathlessness in advanced
diseases and are regularly recommended in the literature. At the time of the previously published Cochrane review, there was no
evidence for a beneficial effect of benzodiazepines for the relief of breathlessness in people with advanced cancer and chronic obstructive
pulmonary disease (COPD).
Objectives
The primary objective of this review was to determine the efficacy of benzodiazepines for the relief of breathlessness in people with
advanced disease. Secondary objectives were to determine the efficacy of different benzodiazepines, different doses of benzodiazepines,
different routes of application, adverse effects of benzodiazepines, and the efficacy in different disease groups.
Search methods
This is an update of a review published in 2010. We searched 14 electronic databases up to September 2009 for the original review.
We checked the reference lists of all relevant studies, key textbooks, reviews, and websites. For the update, we searched CENTRAL,
MEDLINE, and EMBASE and registers of clinical trials for further ongoing or unpublished studies, up to August 2016. We contacted
study investigators and experts in the field of palliative care asking for further studies, unpublished data, or study details when necessary.
Selection criteria
We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) assessing the effect of benzodiazepines compared
with placebo or active control in relieving breathlessness in people with advanced stages of cancer, chronic obstructive pulmonary
disease (COPD), chronic heart failure (CHF), motor neurone disease (MND), and idiopathic pulmonary fibrosis (IPF).
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Data collection and analysis
Two review authors independently assessed identified titles and abstracts. Three review authors independently performed assessment
of all potentially relevant studies (full text), data extraction, and assessment of methodological quality. We carried out meta-analysis
where appropriate.
Main results
Overall, we identified eight studies for inclusion: seven in the previous review and an additional study for this update. We also identified
two studies awaiting classification in this update. The studies were small (a maximum number of 101 participants) and comprised data
from a total of 214 participants with advanced cancer or COPD, which we analysed. There was only one study of low risk of bias.
Most of the studies had an unclear risk of bias due to lack of information on random sequence generation, concealment, and attrition.
Analysis of all studies did not show a beneficial effect of benzodiazepines for the relief of breathlessness (the primary outcome) in
people with advanced cancer and COPD (8 studies, 214 participants) compared to placebo, midazolam, morphine, or promethazine.
Furthermore, we observed no statistically significant effect in the prevention of episodic breathlessness (breakthrough dyspnoea) in
people with cancer (after 48 hours: risk ratio of 0.76 (95% CI 0.53 to 1.09; 2 studies, 108 participants)) compared to morphine.
Sensitivity analyses demonstrated no statistically significant differences regarding type of benzodiazepine, dose, route and frequency of
delivery, duration of treatment, or type of control. Benzodiazepines caused statistically significantly more adverse events, particularly
drowsiness and somnolence, when compared to placebo (risk difference 0.74 (95% CI 0.37, 1.11); 3 studies, 38 participants). In
contrast, two studies reported that morphine caused more adverse events than midazolam (RD -0.18 (95% CI -0.31, -0.04); 194
participants).
Authors’ conclusions
Since the last version of this review, we have identified one new study for inclusion, but the conclusions remain unchanged. There is
no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD. Benzodiazepines
caused more drowsiness as an adverse effect compared to placebo, but less compared to morphine. Benzodiazepines may be considered
as a second- or third-line treatment, when opioids and non-pharmacological measures have failed to control breathlessness. There is a
need for well-conducted and adequately powered studies.
P L A I N L A N G U A G E S U M M A R Y
Benzodiazepines for the relief of breathlessness in advanced diseases in adults
Background
Breathlessness is a common and distressing symptom in advanced cancer and other diseases at the end of life. Treating breathless-
ness sufficiently remains very difficult. Benzodiazepines are a group of sedating medicines (drugs), including lorazepam, clorazepate,
diazepam, alprazolam, and temazepam, that are used mainly for sleep disturbance and anxiety, but are widely used for the relief of
breathlessness.
Key results
In this updated systematic review we aimed to determine whether benzodiazepines relieved breathlessness in adults with advanced
disease. In August 2016, we found eight studies.
Benzodiazepines caused more side effects such as drowsiness or somnolence when compared to placebo but caused less side effects when
compared to morphine. Our review therefore supports the use of benzodiazepines only if other first-line treatments, such as opioids
and non-drug treatments, have failed. However, there is still an urgent need for more studies in this field to find better ways to relieve
this burdensome symptom in people with advanced diseases.
We concluded in summary that there is no evidence that benzodiazepines relieve breathlessness in adults with advanced disease.
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B A C K G R O U N D
This review is an update of a previously published review in the
CochraneDatabase of Systematic Reviews, Issue 1, 2010, on ’Ben-
zodiazepines for the relief of breathlessness in advanced malignant
and non-malignant diseases in adults’.
Description of the condition
The American Thoracic Society defines breathlessness as “a sub-
jective experience of breathing discomfort that consists of quali-
tatively distinct sensations that vary in intensity. The experience
derives from interactions among multiple physiological, psycho-
logical, social, and environmental factors, and may induce sec-
ondary physiological and behavioral responses” (Parshall 2012).
This multidimensional concept of breathlessness as ’total breath-
lessness’ is comparable with the concepts of ’total pain’ or ’total
suffering’ (Booth 2006). The term ’breathlessness’ is used inter-
changeably with dyspnoea, shortness of breath, breathing diffi-
culty, and laboured breathing. Breathlessness is defined as refrac-
tory when it persists despite optimal treatment of the underlying
condition (Dorman 2009), and canmanifest as continuous breath-
lessness or episodic breathlessness (Simon 2012; Simon 2014).
Breathlessness is one of the most common symptoms in the last
year of life (Higginson 2004). In advanced diseases, it is highly
prevalent in chronic obstructive pulmonary disease (COPD) (56%
to 98%), chronic heart failure (CHF) (18% to 88%), and can-
cer (16% to 77%) (Moens 2014). It is a distressing symptom for
the patient, but also for the caregivers (Nordgren 2003). The fre-
quency and severity of breathlessness increases during the course of
the disease until death (Currow 2010; Seow 2011). Furthermore,
breathlessness may be related to anxiety and depression (Neuman
2006), thus treatment of anxiety and depression may reduce this
symptom. However, the contribution, the causal relationship, and
the direction of influence are still unclear (Booth 2008).
Different diseases cause breathlessness, such as primary and sec-
ondary cancer, COPD, CHF, motor neurone disease (MND),
and cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
(IPF). The advanced stage of each disease must be defined sepa-
rately because of the different disease trajectories. The pathophysi-
ology of breathlessness depends mainly on the underlying cause. It
includes, for example, airway obstruction, reduction of lung or gas
exchange capacity, muscle weakness, degeneration of neurons, or
reduction of blood diffusing capacity. The pathological pathway
is complex and beyond a sole reduction of PO2 (partial pressure
of oxygen) or increase of PCO2 (partial pressure of carbon diox-
ide) (Manning 1995). The medulla in the brain stem, the motor
and sensory cortex, peripheral and central chemoreceptors, and
mechanoreceptors in the airways and chest wall are the main sites
of action responsible for the perception of breathlessness (Booth
2008). There are different explanations of how different parts in-
teract and induce the sensation of breathlessness, such as corollary
discharge, afferent-reafferent dissociation, and receptor reaction.
The corollary discharge describes the hypothesis that a sensory
’copy’ of the motor output is sent from the motor cortex to the
sensory cortex and imparts a conscious awareness of respiratory
effort, and is the most widely accepted hypothesis (Beach 2006).
After treatment of the underlying cause, symptommanagement of
breathlessness includes non-pharmacological andpharmacological
interventions. A recentCochrane Review onnon-pharmacological
interventions for the relief of breathlessness in advanced disease
showed effectiveness of neuro-electrical muscle stimulation, chest
wall vibration, walking aids, and breathing training (Bausewein
2008). A recent review on the use of oxygen highlights that there is
a statistically and clinically significant benefit for both ambulatory
and long-term oxygen in COPD, but no consistent evidence for
their use in cancer (Cranston 2008).
Opioids are the first choice in the pharmacological management
of refractory breathlessness. A Cochrane Review showed evidence
for the use of oral and parenteral application of opioids, but there
is currently no evidence for nebulised opioids (Jennings 2001;
Parshall 2012). However, most of the studies were underpowered,
and there is a need for further well-designed studies to investigate
the effectiveness in different diseases, applications, and doses. Be-
sides opioids, there are other drugs for the palliation of breathless-
ness, such as steroids (for lymphangitis carcinomatosa), inhaled
local anaesthetics, or more sedating drugs such as benzodiazepines,
phenothiazines, buspirone, or chlorpromazine, with variable evi-
dence in symptom control (Davis 2005; Parshall 2012).
Description of the intervention
Benzodiazepines are frequently used in themanagement of breath-
lessness in advanced diseases and are regularly recommended in
textbooks for palliative medicine or clinical guidelines (Booth
2006; Bruera 2006). The most common drugs are diazepam, mi-
dazolam, alprazolam, and lorazepam. However, there are more
than 40 different benzodiazepines (Hardman 2005).
How the intervention might work
It is increasingly evident that breathlessness interacts with mental
health, for example anxiety and depression and anxiety or panic
can trigger or worsen breathlessness (Booth 2008; Davis 1997).
Benzodiazepines are anxiolytics, which have sedating effects and
are intended to relieve anxiety and might therefore have palliating
effects for breathlessness.
Benzodiazepines belong to the group of hypnotics and sedatives.
Their core chemical structure is a fusion of the benzene and the
diazepine ring with various modifications that are responsible for
the different compounds of the drug. The interaction of benzo-
diazepines with specific subunits of GABA (gamma-aminobutyric
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acid) receptors is responsible for their mechanism of action. The
central and main effects of benzodiazepines are sedative-hypnotic,
muscle-relaxant, anxiolytic, and anticonvulsant. Side effects in-
clude impairment of mental and motor function, light-headed-
ness, and nausea (Hardman 2005). Physical dependence is a huge
problem in long-term use of benzodiazepines. There is no effect
on respiration (for example depression of respiration) in normal
doses, and only a slight depression of ventilation in higher doses
(Hardman 2005). Themain therapeutic uses are insomnia, anxiety
disorders, acute epilepsy, alcohol withdrawal, and anaesthetic pre-
medication (Hardman 2005). The group of non-benzodiazepines
(for example zolpidem) act on the same receptors with similar ef-
fects, but have a different chemical structure.Wehave not included
these in this review as they do not belong to the benzodiazepine
group.
Why it is important to do this review
Despite the frequent use of benzodiazepines for the relief of breath-
lessness in palliative care, the evidence for their efficacy is still un-
clear.
O B J E C T I V E S
The primary objective of this review was to determine the efficacy
of benzodiazepines for the relief of breathlessness in people with
advanced disease.
Secondary objectives were to determine the efficacy of differ-
ent benzodiazepines, different doses of benzodiazepines, different
routes of application, adverse effects of benzodiazepines, and the
efficacy in different disease groups.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs). We defined
’randomised’ as studies described by the authors as ’randomised’
anywhere in the manuscript.
• Controlled clinical trials (CCTs).
While writing the protocol, we expected a limited number of stud-
ies and therefore decided also to include controlled trials, giving
special consideration to the higher risk of bias in these trials in the
analysis.
Types of participants
Adult participants described as suffering from either breathless-
ness, dyspnoea, shortness of breath, difficult breathing, or laboured
breathing due to advancedmalignant and non-malignant diseases.
The advanced stages of diseases included the following.
• Cancer: advanced local or metastatic disease.
• COPD: stage III (severe) or IV (very severe) according to
the Global Initiative for Obstructive Lung Disease (GOLD)
classification. This includes people with airflow limitation of
FEV1 < 50%, FEV1/FVC < 0.7 (FEV1: forced expiratory
volume in one second; FVC: forced vital capacity) and
symptoms such as more severe breathlessness, reduced exercise
capacity, and repeated exacerbations (GOLD 2007).
• CHF: stage III or IV of the New York Heart Association
(NYHA) classification including symptoms such as
breathlessness or palpitation and an increasing limitation of
exercise capacity and discomfort at rest.
• MND: all participants suffering from breathlessness.
• IPF: all participants suffering from breathlessness as the
most prominent and disabling symptom.
We excluded studies including participants with acute or chronic
asthma, pneumonia, or other potentially curable diseases. Partic-
ipants included in the studies could be in any care setting (for
example hospital or home care).
We included studies evaluating participants on oxygen as long as
oxygen was used in both the intervention and the control arm.
Types of interventions
The use of benzodiazepines (at any dose, any frequency (also sin-
gle dose), any duration, and through any route) for the relief of
breathlessness compared with placebo or active control. We in-
cluded all drugs that belong to the pharmacological group of ben-
zodiazepines (Hardman 2005).
Types of outcome measures
Primary outcomes
Primary outcomes included subjective measurements of breath-
lessness on validated and reliable scales such as:
• uni-dimensional scales (e.g. visual analogue scales (VAS),
numeric rating scales (NRS), categorical scales, modified Borg
scales); or
• multidimensional scales (e.g. St. George’s Respiratory
Questionnaire (SGRQ), Chronic Respiratory Disease
Questionnaire (CRQ)).
We included studies that measured breathlessness as a primary or
secondary outcome, and also studies evaluating breathlessness at
rest or on exercise.
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Secondary outcomes
Secondary outcomes included:
1. measurement of anxiety;
2. measurement of depression;
3. adverse effects of benzodiazepines;
4. functional exercise capacity (e.g. walking tests);
5. measurement of quality of life; and
6. attrition.
Search methods for identification of studies
We ran the search for the original review on 12 September 2009
and ran a subsequent search on 23 August 2016.
Electronic searches
For the original review, we identified studies from a search of the
following 14 databases:
• the Cochrane Pain, Palliative and Supportive Care Trials
Register (12 September 2009);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (2009, Issue 3) (12
September 2009);
• the Cochrane Database of Systematic Reviews (CDSR) in
the Cochrane Library (12 September 2009);
• Database of Abstracts of Reviews of Effects (DARE) (12
September 2009);
• MEDLINE (1950 to 12 September 2009);
• EMBASE (1980 to 12 September 2009);
• CINAHL (1980 to 12 September 2009);
• PsycINFO (1806 to 12 September 2009);
• American College of Physicians (ACP) Journal Club (12
September 2009);
• Health Technology Assessment (HTA) Database (12
September 2009);
• NHS Economic Evaluation Database (NHSEED) (12
September 2009);
• Database of Halley Stewart Library (St. Christopher’s
Hospice) (12 September 2009);
• International Pharmaceutical Abstracts (1970 to 12
September 2009); and
• Iowa Drug Information System (IDIS) (1966 to 12
September 2009).
For the update, we searched:
• CENTRAL Issue 7 2016 (the Cochrane Library) (searched
2009 to 2016);
• MEDLINE & Medline in Process (OVID) (Sept 2009 to
23 August 2016);
• EMBASE (OVID) (September 2009 to 23 August 2016).
We decided not to search the other databases searched for the
original review as they did not yield any useful records.
We searched the following study registers or meta registers of clin-
ical trials for ongoing or unpublished studies for the update:
• ClinicalTrials.gov (08 July 2016);
• metaRegister of Controlled trials (mRCT) - active registers
(08 July 2016);
• WHO International Clinical Trials Registry Platform (08
July 2016).
We again contacted study investigators and experts in the field of
palliative care to ask for further studies, unpublished data, or study
details when necessary.
Please see Appendix 1 for the search strategies applied in the orig-
inal review. Appendix 2 shows the search strategies applied in this
update, with minor changes in lines 3 and 5 (in line 3 to ensure
that both British and US spellings of labour/labor were picked up;
in line 5 to ensure that both of the phrases ’shortness of breath’
and ’short of breath’ were included).
Searching other resources
Handsearching
We checked the reference lists of all relevant studies, key textbooks,
and key websites for further relevant studies. We checked the refer-
ence lists of several reviews on the subject (Abernethy 2008; Allen
1984; Altose 1985; Bausewein 2008; Booth 2008; Davis 1997;
De Conno 1991; Lanken 2008;Manning 2000; Ripamonti 1999;
Rocker 2007;Runo 2001;Thomas 2002;Tobin 1990;Viola 2008;
Williams 2006).
We handsearched the reference lists of the following 16 textbooks:
Goodman and Gilman’s The Pharmacological Basis of Therapeu-
tics; Oxford Textbook of Palliative Medicine; Textbook of Palliative
Medicine;Textbook of Palliative Nursing; Palliative Medicine;Man-
agement of Advanced Disease;Palliative Care Formulary 3; Oxford
Handbook of Palliative Care; Palliative Medicine - a Case-Based
Manual; Principles and Practice of Palliative Care and Supportive
Oncology; Dyspnoea in Advanced Disease; Dyspnoea; Heart Failure
and Palliative Care; Supportive Care in Respiratory Disease;Textbook
of Respiratory Medicine; and Palliative Care in Neurology.
In addition, we searched seven websites to identify relevant data:
www.benzo.org.uk; www.book.palliative.info;
www.caresearch.com.au; www.cks.library.nhs.uk;
www.controlled-trials.com; www.palliativedrugs.com; and
www.patient.co.uk.
We undertook no further handsearches for this review update.
Personal contact
We contacted the following authors of main studies and inves-
tigators who are known to be carrying out research in this area
for further studies and unpublished data for the original review:
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Amy Abernethy, Sam Ahmedzai, Eduardo Bruera, Leandro Cer-
chietti, Jessica Corner, David Currow, Carol Davies, Deborah
Dudgeon, Wesley Ely, Tim Harrison, Michio Hosaka, Miriam
Johnson, AlfredoNavigante, AndrewWilcock, and AshleyWood-
cock. In addition, we asked all members of the Association of
Palliative Medicine (UK) and all users of the bulletin board of
www.palliativedrugs.com in a circular letter for additional studies
or unpublished data. For the update, we contacted the above men-
tioned experts again and also asked the following newly identified
study investigators for further information on their studies: Scott
Bolesta, Eliza S. Daubert, Diana E. Hart, Neil K Hiliard, Fiona
Horwood, Clare Randall, and Gerben Stege.
Language
There was no language restriction in the selection of studies.
Data collection and analysis
Selection of studies
Two review authors (STS, CB in the original review; VW, STS in
the update) independently assessed the relevant titles and abstracts
identified. Disagreement was resolved by consensus and with a
third review author (IJH in the original review; CB in the update).
Three review authors (STS, CB, SB in the original review; VW,
STS, CB in the update) independently assessed the full text of
all potentially relevant studies, and disagreement at this stage was
again resolved by consensus andwith a fourth review author (IJH).
Data extraction and management
Three review authors (STS, CB, SB) independently extracted data
from each appropriate study in the original review; two review au-
thors (STS, VW) did this for the update. We specifically designed
an extraction form for collection of relevant data consisting of:
Study ID and publication details, including:
• study aim.
Study design and methods, including:
• randomisation procedure;
• allocation concealment;
• details of blinding;
• number and time of follow-ups;
• handling of missing data; and
• details of analysis.
Participant characteristics, including:
• demographics;
• diagnosis;
• performance status;
• number and description of participants in the intervention
and control groups; and
• setting.
Intervention, including:
• the drug and its characteristics (e.g. half-life);
• route of administration;
• dose;
• frequency of application;
• duration of therapy; and
• description of placebo.
Primary outcomes, including:
• measurement of breathlessness; and
• change in level of breathlessness.
Secondary outcomes, including:
• adverse effects of benzodiazepines;
• functional exercise capacity;
• dose modification;
• number and reason of withdrawals/attrition;
• measurement of anxiety;
• measurement of depression;
• measurement of quality of life; and
• arterial blood gas measurements.
Additional information, including:
• participant comments on intervention.
Methodological quality, including:
• Risk of bias table (according to Cochrane standard);
• Edwards Method Score (11 items as described below).
We contacted authors of studies to provide unpublished data for
the meta-analysis where required.
Assessment of risk of bias in included studies
Three review authors (STS, CB, SB in the original review; STS,
VW in the update) independently assessed all selected studies for
methodological quality. We used two measures of methodological
quality. Firstly, we assessed the quality of studies using the Re-
view Manager (RevMan) ’Risk of bias’ table, categorising them as
’low risk’, ’high risk’, or ’unclear risk’ according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011;
RevMan 2008; RevMan 2014). Secondly, we graded the quality of
studies according to the Edwards Method Score (Edwards 2001;
Edwards 2003). This checklist of methodological quality contains
11 items that assess the primary research quality of the studies and
its published description. The following items were assessed and
scored zero, one, or two for adequacy: definition of aims; sample
formation; description of inclusion and exclusion criteria; descrip-
tion of participant characteristics; power calculation; objectivity
of outcome measures used; adequacy of follow-up; adequacy of
analysis (intention-to-treat (ITT)); adjustment for baseline differ-
ences between groups; appropriate unit of allocation to groups;
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and randomisation method. We then constructed a total method
score (max 22) and rated the overall quality of the studies as fol-
lows: low (12 and under), medium (13 to 14), high (15 and over)
(Edwards, personal communication). We integrated the results of
the quality assessment in data analysis, as well as in meta-analysis
(cumulative meta-analysis only in high-quality studies).
Measures of treatment effect
We used primary and secondary outcomes in the meta-analysis
when appropriate and possible. The primary outcome measures
(breathlessness) were either in the form of continuous or ordinal
data. We treated all ordinal data as continuous data because the
scales used were long enough (following the recommendation of
the Cochrane Handbook, Higgins 2011). In the meta-analysis, we
treated studies with cross-over design in the same way as studies
with a parallel design if there was no indication of a carry-over
effect (following the advice of the Cochrane Handbook and after
discussion with the statistician of the Cochrane Review Group)
(Higgins 2011). We judged the potential existence of a carry-over
effect on a theoretical basis after analysis of the study (for example
drug persistency in the body into the next period). We estimated
the effect by comparing the post-treatment measurements of the
intervention and the control groups. We calculated the standard-
ised mean differences (SMD) for continuous data with a 95%
confidence interval (CI) to show the size of the effect of interven-
tions.Due to the diversity ofmeasurement tools for breathlessness,
we used SMD to measure the intervention effect in standardised
units. A negative SMD was defined as a beneficial effect of the
intervention. We calculated the risk ratio (RR) for dichotomous
data to estimate the relative risk. We used risk difference when
there was no event in one of the groups (for example for adverse
effects or attrition), because the estimation of RR is not possible
in this case. For all data we considered a P value of less than 0.05
as statistically significant.
Unit of analysis issues
We combined cross-over trials and studies with a parallel design
in the meta-analysis and treated the cross-over studies as parallel
design. We did this after a critical analysis of all studies, review of
the literature (Elbourne 2002; Higgins 2011), discussion with a
statistician, and the following judgements:
1. the cross-over design was suitable for the targeted research
questions;
2. none of the cross-over studies showed evidence of a carry-
over effect;
3. dropouts were excluded from analysis;
4. there was no evidence for a period effect. This approach can
produce a unit-of-analysis error.
Dealing with missing data
When means and standard deviations (SD) were missing, we did
not impute or estimate them for meta-analysis, because none of
the suggested imputations in the Cochrane Handbook for System-
atic Reviews of Interventions were reliable (after consultation with
the statistician of the Cochrane Review Group) (Higgins 2011).
We therefore contacted the authors for additional data (means and
SD). If they could not provide means or SD, we asked for the orig-
inal data and calculated means and SD from these data. Data were
only retrieved from graphs if exact numbers could be determined.
With this procedure, we were able to retrieve all relevant data.
Assessment of heterogeneity
We anticipated clinical heterogeneity because of the differences in
diagnostic groups, participants’ disease, types of benzodiazepines,
doses, duration of treatment, and route of delivery. We measured
the impact of statistical heterogeneity (of effects) by quantifying
inconsistency using the I2 statistic and based its interpretation on
the recommendations given in the Cochrane Handbook (Higgins
2011).
Assessment of reporting biases
We assessed selective outcome reporting but did not assess further
forms of reporting bias (no further assessment than those included
in the ’Risk of bias’ tool).
Data synthesis
We combined studies using RevMan (Version 5.0 for the origi-
nal review, Version 5.3 for the update) (RevMan 2008; RevMan
2014). We attempted to obtain all relevant data from each paper.
We performed a meta-analysis including all appropriate studies.
We excluded studies from the meta-analysis if the methodological
quality of the studywas low (EdwardsMethodScore 12 and lower).
Weused a random-effectsmodel because clinical heterogeneitywas
present. We used the fixed-effect model only for the presentation
of single studies or for studies with adequate homogeneity.
Subgroup analysis and investigation of heterogeneity
See section Assessment of heterogeneity.
Sensitivity analysis
Weundertook sensitivity analysis to look for influences of different
variables (for example participants, interventions, outcomes, and
study design). We also performed sensitivity analysis taking into
account methodological quality and the robustness of results.
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R E S U L T S
Description of studies
We have illustrated the study selection process for the update of
this review in Figure 1.
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Figure 1. Study flow diagram.
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Results of the search
For the update, we included eight studies in total (Eimer 1985,
Harrison (unpublished), Man 1986, Navigante 2006, Navigante
2010 (updated data which was an unpublished study in the ear-
lier review), Shivaram 1989, Stege 2010 (this study was awaiting
assessment in the earlier review), Woodcock 1981). In addition
in this update, we included two study for awaiting classification
(Hart 2012, Hardy 2016).
For the earlier review, we identified a total of 1309 references
through the search of 14 databases. We excluded 207 duplicates.
We studied the titles and abstracts of each of the 1102 articles and
selected relevant articles if they met the inclusion criteria. In the
earlier review, we sorted the 1071 excluded articles into the fol-
lowing exclusion groups: different disease (241 articles), different
drug (223), reviews (242), anaesthesia-related study (111), psy-
chology-related study (61), pharmacokinetic study (45), different
design (38), palliative/terminal sedation (37), non-pharmacolog-
ical interventions (14), and other (for example children) (59). We
retrieved 31 articles for more detailed evaluation in the original
review. In the earlier review, we identified 48 additional references
from the reference lists of the original 31 articles by handsearching
and the auxiliary function ‘Related Articles’ in Science Direct (
www.sciencedirect.com). The search of 59 reviews, 16 textbooks,
and seven websites did not yield any new articles. For the earlier
review, we studied a total of 79 articles in more detail after obtain-
ing the full text. Of these 79 articles, seven studies met our inclu-
sion criteria and were included in the earlier review, and one study
was awaiting classification (Stege 2010). We excluded a total of 74
articles for the earlier review. In addition, after sending a letter to
all members of the Association of Palliative Medicine (UK) and
after personal contact with several investigators (see above) at time
of the original review, we were able to identify three new and un-
published studies (Harrison (unpublished),Navigante 2010, Stege
2010). We received data from two out of the three unpublished
studies which we could include in the earlier review (Harrison
(unpublished), Navigante 2010). The author of the third study
could not send the data before submission and was set for “await-
ing classification” of the earlier review (Stege 2010).
For the update of the review, we identified 1884 records: 32 ar-
ticles in CENTRAL, 92 in MEDLINE, and 1760 in EMBASE.
We also identified one potentially relevant clinical study report in
trial registries. After de-duplication, there were 1769 articles for
assessment. After screening titles and abstracts and exclusion of
1749 studies (see Figure 1 for reasons of exclusion) we obtained
full copies of 19 published studies and one study from trial reg-
istries. Of these 20 records, we excluded 17 studies and the record
from trial registries (this was a pilot study which failed to recruit
any participants and was therefore excluded (NCT01687751, per-
sonal communication with Neil Hilliard, June 2015)). One of the
excluded records was a study protocol only, and the study was can-
celled early before any participants were included (Daubert 2014;
personal communication with Eliza Daubert and Scott Bolesta in
June 2015). Two additional studies were considered for awaiting
classification. One out of these two studies was published only as
a conference abstract and we received no data until the time of
submission of the review (see Characteristics of studies awaiting
classification) (Hart 2012). The second study was published just
before the submission of this review and the data will be con-
sidered at the next update (conclusion of this study supports the
conclusion of the review) (see Characteristics of studies awaiting
classification) (Hardy 2016). Finally for the update, we added one
new study to the seven studies of the original review (Stege 2010
- this study was unpublished and awaited assessment in the earlier
review). In addition, we updated data of one previously unpub-
lished but previously included study (Navigante 2010).
Included studies
See Characteristics of included studies.
Eimer 1985: a double-blind, placebo-controlled, cross-over RCT
tested clorazepate in five non-anxious participants with severe
COPD in a hospital setting to determine whether relieving breath-
lessness could be achieved. The study started with three arms (7.5
mg/day and 22.5 mg/day oral clorazepate compared to placebo),
but the high-dose arm (22.5 mg) was excluded from analysis after
3 out of 5 participants dropped out due to intolerable adverse ef-
fects. The duration of treatment was two weeks with a one-week
wash-out period. Breathlessness was assessed weekly with a Breath-
lessness Grade from 1 (little breathlessness) to 6 (extreme breath-
lessness). Secondary outcomes were anxiety, depression, adverse
effects, a 12-minute walking test, and attrition.
Harrison (unpublished): the effectiveness of lorazepam in the re-
lief of breathlessness was tested in a randomised, double-blind,
placebo-controlled, cross-over study of 26 participants with ad-
vanced cancer in an in- and outpatient setting (single-centre). Sev-
enteen participants completed the study and were included in the
analysis. The study tested lorazepam 0.5 mg twice daily orally
over five days with a two-day wash-out period. A visual analogue
scale (VAS) (0 to 100) was used to measure breathlessness as pri-
mary outcome (responding to three questions: 1. breathlessness
in general over the last 24 hours (summary); 2. breathlessness at
its best over the last 24 hours; and 3. breathlessness at its worst
over the last 24 hours). Secondary outcomes were anxiety and de-
pression (measured on the Hospital Anxiety and Depression Scale
(HADS)) and adverse effects after the treatment.
Man 1986: a double-blind, placebo-controlled, cross-over RCT of
29 participants with advanced but clinically stable COPD in an
outpatient setting assessed the efficacy and safety of alprazolam in
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relieving breathlessness. The analysis included 24 participants, and
five participants dropped out. The study compared the effect of
alprazolam 1.0 mg/day orally to placebo before and after one week
of treatment (with a one-week wash-out period after cross-over).
Breathlessness was measured either by Grade of Dyspnoea with 5
(breathlessness at rest) to 2 (able to keep up with people of similar
age on level, but not on hills and stairs) to 1 (other than 2 to 5), as
well as with a Dyspnoea Scoring (VAS 0 to 10) at rest and during
exercise (bicycle ergometer). The study measured adverse effects,
attrition, and a 12-minute walking test as additional outcomes.
Navigante 2006: a single-blind RCTwith a parallel design assessed
the role of midazolam in the alleviation of severe breathlessness
during the last week of life of 101 participants with advanced can-
cer. The investigators conducted a three-arm trial in a hospital
setting comparing morphine only (10 mg/day), midazolam only
(20 mg/day), and the combination of morphine plus midazolam
(10 plus 20 mg/day), with a treatment duration of 48 hours and
subcutaneous administration. The dose was adjusted if the partici-
pant was not morphine naive (+25% on top of daily subcutaneous
equivalent dose of morphine). Rescue medication was provided
with 5 mg midazolam in the morphine group and 2.5 mg mor-
phine in the midazolam and midazolam plus morphine group.
Breathlessness was the primary outcome, assessed in four different
ways:
1. Breathlessness intensity with the modified Borg scale (0 to
10) before the intervention and 24 and 48 hours after
intervention;
2. Percentage of participants with breathlessness relief (yes/no)
after 24 and 48 hours and no breathlessness relief after 48 hours;
3. Numbers of episodes of breathlessness (’breakthrough
dyspnoea’ = numbers of rescue medication) per participant after
24 and 48 hours; and
4. Percentage of participants with episodic breathlessness after
24 and 48 hours.
Other outcomeswere adverse effects (total of clinical relevance and
different adverse effects in grading 1 to 3), anxiety, and attrition.
Navigante 2010: a single-blind RCT with a parallel design was
undertakenwith 63 participants with advanced cancer and breath-
lessness in a single-centre outpatient clinic (two participants
dropped out after randomisation). The aim was to assess the effi-
cacy of oral midazolam for the relief of breathlessness in compar-
ison to oral morphine. A fast titration phase (FTP) was used to
determine the effective dose (effect of at least 50% reduction of
breathlessness) for the follow-up phase (FUP) starting with mida-
zolam 2 mg every four hours (excluding sleeping time) and mor-
phine 3 mg every four hours (excluding sleeping time) with incre-
mental steps of 25% of the preceding dose every 30 minutes. The
duration of treatment in the FUP was five days with daily assess-
ment of the primary endpoint breathlessness intensity (numeric
rating scale (NRS), 0 to 10) and the secondary outcomes number
of episodes of breathlessness per day, descriptors the participant
used for breathlessness, and the number of adverse effects. The
study reported dose reduction, therapeutic failure, and additional
procedures (for example antibiotics).
Shivaram 1989: a double-blind, randomised, placebo-controlled,
cross-over study of 12 participants with advanced COPD with
anxiety (non-psychiatric stage) in an unknown setting (probably
hospital) assessed the effect of alprazolam to relieve breathless-
ness. Four participants dropped out and were excluded, leaving
eight participants for analysis. The study compared the effect of
oral alprazolam 0.75 mg/day to placebo at baseline and after two
weeks of treatment (with two days wash-out). Breathlessness was
measured on a modified Borg scale (0 to 10). No other outcomes
except adverse effects were assessed.
Stege 2010: a double-blind, randomised, placebo-controlled,
cross-over study of 17 participants with COPD (Global Initiative
for Obstructive Lung Disease (GOLD) stages 3 or 4) with insom-
nia in an outpatient centre of a respiratory medicine hospital de-
partment. The aim of the study was to assess whether temazepam
(10 mg daily over one week) influences indices of breathing and
gas exchanges during sleep; the effect on dyspnoea sensation (as-
sessed with 10-point VAS) and other outcomes were secondary
objectives. Three participants dropped out, leaving 14 participants
for analysis.
Woodcock 1981: a double-blind, placebo-controlled, cross-over
RCT of 18 participants with severe COPD compared the effect
of oral diazepam (25 mg/day) and promethazine (125 mg/day) on
breathlessness. Three participants dropped out, leaving 15 partic-
ipants for analysis. Breathlessness was the main outcome, assessed
as ’daily dyspnoea’ byVAS (0 to 10) and ’dyspnoea grade’ 5 (breath-
lessness at rest) to 2 (able to keep up with people of similar age on
level, but not on hills and stairs) to 1 (other than 2 to 5), after each
intervention in an outpatient setting with a two-week treatment
duration (no wash-out period). The study assessed adverse effects,
dose modification, anxiety, depression, a 12-minute walking test,
treadmill, and ergometer measurement.
Study design
All studies were RCTs (Eimer 1985; Harrison (unpublished);
Man 1986; Navigante 2006; Navigante 2010; Shivaram 1989;
Woodcock 1981). Besides Navigante 2006 and Navigante 2010,
who used a single-blind, parallel, and morphine-controlled de-
sign, all other studies were double-blind, cross-over, and placebo-
controlled (Eimer 1985; Harrison (unpublished); Man 1986;
Shivaram 1989; Stege 2010; Woodcock 1981).
Sample size
In general, the sample size was small (between five and 29 par-
ticipants), except for two studies of Navigante and colleagues
(Navigante 2006 with 101 participants and Navigante 2010 with
63 participants). One study finished data collection without drop-
outs (Eimer 1985). Five studies had between three and nine
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dropouts (dropout/N: 9/26, 5/29, 4/12, 3/17, 3/18) (Harrison
(unpublished);Man 1986; Shivaram1989; Stege 2010;Woodcock
1981); one study lost two of 63 participants (Navigante 2010);
and one study lost 31 participants due to death during the
study (Navigante 2006), which were always excluded from the
analysis. Four studies provided a power calculation (Harrison
(unpublished); Navigante 2010; Shivaram 1989; Stege 2010),
and three of them reached an appropriate number of participants
(Navigante 2010; Shivaram 1989; Stege 2010). None of the stud-
ies presented an intention-to-treat analysis. A total of 214 partic-
ipants were analysed, including 33 participants of the third inter-
vention arm of the parallel-designed study from Navigante 2006.
Participants
Three studies included participants with cancer (Harrison
(unpublished); Navigante 2006; Navigante 2010), and five studies
included participants with advanced COPD (Eimer 1985; Man
1986; Shivaram 1989; Stege 2010; Woodcock 1981).
Outcomes
Breathlessness intensity was measured mainly on a VAS/NRS
(Harrison (unpublished); Man 1986; Navigante 2010; Stege
2010; Woodcock 1981), a modified Borg scale (Navigante 2006;
Shivaram 1989), and a Dyspnoea Grade 1 to 6 scale or 1 to 5
scale (Eimer 1985; Man 1986; Woodcock 1981). The majority
of studies measured breathlessness at rest (Eimer 1985; Harrison
(unpublished); Navigante 2006; Navigante 2010; Shivaram
1989); only three studies also assessed breathlessness on exercise
(Eimer 1985; Man 1986; Woodcock 1981). Two studies assessed
episodic breathlessness (Navigante 2006; Navigante 2010), and
one study did not further specify breathlessness (Stege 2010).
Other outcomes were anxiety (Harrison (unpublished); Navigante
2006; Woodcock 1981), depression (Harrison (unpublished);
Woodcock 1981), adverse effects (all), walking tests (Eimer 1985;
Man 1986; Woodcock 1981), and attrition (all).
Intervention
Two studies tested alprazolam, one with 1.0 mg/day (Man 1986),
and one with 0.75 mg/day (Shivaram 1989). One study tested
25 mg/day diazepam within a three-arm design with 125 mg/day
promethazine compared to placebo (Woodcock 1981). Navigante
2006 applied midazolam 20 mg/day only and in combination
withmorphine 10mg/day compared tomorphine 10mg/day only
within a three-arm design. Navigante 2010 studied oral midazo-
lam 8 mg/day versus morphine 12 mg/day (both starting doses).
Harrison (unpublished) examined lorazepam 1 mg/day. Eimer
1985 tested two different doses of clorazepate, 7.5 and 22.5 mg/
day, compared to placebo; however, due to intolerable adverse ef-
fects, the 22.5 mg arm was excluded from analysis. Stege 2010 ex-
amined the effect of temazepam 10 mg/day orally. The treatment
durations ranged between 48 hours, in Navigante 2006, and two
weeks, in Eimer 1985, Shivaram 1989, and Woodcock 1981.
Excluded studies
See Characteristics of excluded studies.
We excluded 90 out of 97 full-text publications because they did
not meet the inclusion criteria (30 ’no subjective measurement of
breathlessness’; 24 ’reviews’; 15 ’different drugs’; six ’different dis-
ease/healthy participant’; three ’combination of drugs’; six ’differ-
ent study design’, two ’guidelines’, two ’editorials’, and two studies
’failed in recruiting any participants’. We excluded a substantial
number of studies because of a lack of subjective measurement
of breathlessness, mainly older studies from the 1970s and 1980s
that studied benzodiazepines in relation to spirometry, functional
tests, or blood tests. Among them is the most cited paper in this
area (Mitchell-Heggs 1980a), which we had to exclude because of
a lack of subjective measurement of breathlessness. Although the
authors mentioned breathlessness as an outcome, we could deter-
mine no subjective measure, either in the text, tables, or graphs.
Other reasons for excluding this study were the lack of system-
atic or standardised design and absence of control group. Four
excluded studies used benzodiazepines only in combination with
other drugs (Clemens 2011; Lichterfeld 1967; Navigante 1997;
Navigante 2003), thus a separate assessment of the drug effect
was not possible. Three excluded studies assessed breathlessness in
healthy people (comparing diazepam, promethazine, and placebo)
(Jones 1985; Stark 1981a; Stark 1981b). One study compared di-
azepam versus flupenthixol in people with psychosomatic disor-
ders (breathlessness was only one of 12 associated symptoms and
was not the primary outcome) (Jokinen 1984). Although we ex-
pected to find a substantial number of observational studies, there
were only a few thematically relevant non-controlled or retrospec-
tive studies, which we had to exclude. Among them was the case
report fromGreene 1989, a non-controlled phase II study (Allcroft
2013), the above-mentioned non-controlled study on the com-
bined use of opioids and benzodiazepines (Clemens 2011), a ret-
rospective study on the management of dyspnoea in hospitalised
palliative-care patients (Gomutbutra 2013), and a prospective ob-
servational study on the patterns of benzodiazepine use among
older adults with COPD in Canada (Vozoris 2013). We excluded
the study Hosaka 1996 because four of the 22 participants did
not meet our inclusion criteria regarding the underlying disease
(asthma, tuberculosis), and the level of airways obstruction was
above our inclusion criteria (mean FEV1 63% and FEV1/FVC
1.06), indicating that the disease stage was not as advanced as re-
quired for this review. This non-randomised, placebo-controlled,
double-blind, cross-over trial studied the use of diazepam 10 to
12 mg/day over four weeks in 22 people with chronic respira-
tory insufficiency (mainly COPD and fibrosis) who received home
oxygen therapy. The study, which was published in Japanese (ab-
stract in English), showed a statistically significant improvement
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in breathlessness at rest in the diazepam group and a statistically
non-significant worsening in the placebo group, but the levels of
breathlessness at baseline were different between the groups.
In the search for the update, we excluded the potentially relevant
studies of Daubert 2014 and NCT01687751 (identified through
register search), because no participants could be recruited in these
trials and no future results are expected (personal communication
with Neil Hilliard, Eliza Daubert and Scott Bolesta in June 2015).
Studies awaiting classification
In the update, we identified one potentially relevant study with the
database search (Hart 2012), and one potentially relevant study
in the clinical trial registries (Hardy 2016) (see Characteristics of
studies awaiting classification).
Hardy 2016 is a randomised, placebo-controlled, cross-over trial
testing the hypothesis that intranasal midazolam is superior to
placebo for the palliation of dyspnoea in people with optimally
treated life-limiting disease. A sample size of 200 participants was
planned but the study was terminated after interim analysis of
75 participants showing no difference between intervention arms.
The primary outcome was breathlessness intensity at 15 min com-
pared to baseline. There was no difference at any time points in
breathlessness scores between arms. This study concludes that in-
tranasal midazolam had no clinical benefit over intranasal placebo
for the control of breathlessness.
The aim of the randomised, double-blind, double-dummy,
placebo-controlled pilot study of Hart 2012 was to compare the
efficacy of intranasal midazolamwith that of oral lorazepam tablets
in relieving dyspnoea in people with severe respiratory disease.
The study included 30 participants, and the findings showed a
“worthwhile improvement in symptom control of dyspnoea and
quality of life” (Hart 2012). Unfortunately, this study was only
published as a conference abstract, and we did not receive data
from the authors at time of the submission (personal contact with
Dr. Hart in August 2016).
Risk of bias in included studies
See Characteristics of included studies, the corresponding ’Risk of
bias’ tables, Figure 2, and Figure 3.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
In the update, seven studies, Harrison (unpublished), Man 1986,
Navigante 2006, Navigante 2010, Shivaram 1989, Stege 2010,
andWoodcock 1981, showedhigh quality on theEdwardsMethod
Score (Edwards 2001; Edwards 2003). Only one study had a high
risk of bias due to lack of presented data and information and
inappropriate presentation of data in figures (Eimer 1985). We
therefore did not include this study in the meta-analysis.
Allocation
All studies were RCTs. Four studies did not mention the denom-
inator population that was screened for participation (Man 1986;
Navigante 2010; Shivaram 1989; Woodcock 1981). There was
a substantial gender imbalance due to more males than females
participating in most studies (exact total numbers are not count-
able because of a different presentation of data for gender of ran-
domised or analysed participants); only Navigante 2006 included
more females than males. One study did not mention the gender
distribution (Navigante 2010).
Blinding
Two studies were single-blinded (Navigante 2006; Navigante
2010); one study did not define blinding appropriately, but was
stated to be double-blind (Eimer 1985); and the rest used a dou-
ble-blind design.
Incomplete outcome data
Seven studies with dropouts excluded them from the analysis (
Harrison (unpublished); Man 1986; Navigante 2006; Navigante
2010; Shivaram 1989; Stege 2010;Woodcock 1981). None of the
studies mentioned missing data or the handling of missing data.
Selective reporting
Woodcock 1981 stated that there was no effect of diazepam in
the relief of breathlessness. However, a beneficial effect could be
seen for diazepam, although it was not statistically significant (P
= 0.06). Stege 2010 stated that no respiratory adverse events had
occurred, however there was no information on other than respi-
ratory adverse events.
Other potential sources of bias
Seven studies were published in indexed, peer-reviewed jour-
nals (Eimer 1985; Man 1986; Navigante 2006; Navigante 2010
Shivaram 1989; Stege 2010; Woodcock 1981), and one study
was unpublished (Harrison (unpublished)). The author of the
unpublished study sent us all the original data at time of the
original review and was very helpful and supportive (Harrison
(unpublished)). One study did not mention a wash-out pe-
riod between intervention and control phases (cross-over design)
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(Woodcock 1981). However, sensitivity analysis showed no differ-
ence regarding the results compared to studies including a wash-
out period. Navigante 2006 used the comparative drug (midazo-
lam plus morphine) for rescuemedication. Since this combination
of midazolam and morphine could have been used in all three
treatment arms, a confident comparison or distinction between
midazolam and morphine was not possible. Navigante 2010 al-
lowed the use of treatments with potential impact on breathless-
ness besides the intervention and the control in the study (for ex-
ample antibiotics, aspiration of pleural effusion, radiotherapy).
Effects of interventions
We included eight studies (eight RCTs; six cross-over and two
parallel designs; five COPD and three cancer studies) in the review
with a total of 214 participants analysed (COPD, N = 66; cancer,
N = 148). We have summarised the main findings of each of
the studies below (see also the Characteristics of included studies
tables). We carried out the meta-analysis separately for placebo-
controlled studies, Harrison (unpublished), Man 1986, Shivaram
1989, Stege 2010, andWoodcock 1981, andmorphine-controlled
studies (Navigante 2006; Navigante 2010).
Benzodiazepines for breathlessness in chronic
obstructive pulmonary disease (COPD)
Eimer 1985
Five participants with advanced COPD were examined in a ran-
domised, cross-over trial. Breathlessness was measured at rest and
after a 12-minute walking test, after two weeks of treatment with
clorazepate 7.5mg/day compared toplacebo. All participants com-
pleted the study. The change scores from baseline to postinterven-
tion showed no statistically significant difference between the in-
tervention and the control group. The results were presented only
in a figure without exact data, which was difficult to interpret.
Man 1986
Twenty-nine participants with advanced COPDwere randomised
in a cross-over design to alprazolam1.0mg/day or placeboover one
week, but only 24 participants completed the study (five dropouts
were excluded from analysis). There was no statistically significant
effect of alprazolam versus placebo compared to baseline in the
relief of breathlessness at rest and on exercise. Furthermore, no
difference between the intervention and the control group was
observed after treatment.
Shivaram 1989
Twelve participants with advanced COPD were randomised
(cross-over), of which only eight participants completed the study
(four dropouts were excluded from analysis). There was no im-
provement of breathlessness at rest with alprazolam 0.75 mg/day
compared to baseline after two weeks, but there was an improve-
ment with placebo (not statistically significant). Furthermore, no
difference was observed after treatment between the intervention
and the control group.
Stege 2010
Seventeen participants with advancedCOPDwho experienced in-
somnia were randomised (cross-over), of which 14 were analysed,
excluding three dropouts. There was no difference of breathless-
ness intensity with temazepam 10 mg/day for one week compared
to placebo.
Woodcock 1981
Eighteen participants with advanced COPD were randomised in
a cross-over design to determine the effect of diazepam 25 mg/day
in the relief of breathlessness compared to placebo and promet-
hazine 125 mg/day (third arm). There were three dropouts, and
15 participants completed the study and were included in the
analysis. Diazepam produced a statistically non-significant effect
in the relief of breathlessness at rest compared to placebo after two
weeks. There was also no difference in breathlessness on exercise
compared to placebo.
Meta-analysis and summary
We included four out of five cross-over studies (see Risk of bias in
included studies) with a total of 61 participants with COPD (122
observations) in the meta-analysis (Man 1986; Shivaram 1989;
Stege 2010; Woodcock 1981) (Analysis 2.1), comparing post-
treatment measures between intervention and control groups. We
observed no statistically significant effect of alprazolam, diazepam,
or temazepam with a standardised mean difference (SMD) esti-
mated as -0.12 (95% confidence interval (CI) -0.52 to 0.29). The
overall heterogeneity of effects was low (I2 = 18%).
Overall, the analysis (five studies) and meta-analysis (four studies)
with 66 and 61 participants, respectively, showed no statistically
significant effect of four different benzodiazepines (clorazepate,
diazepam, alprazolam, temazepam) in the relief of breathlessness
in people with advanced COPD. One study showed a slight but
statistically non-significant advantage of diazepam compared to
placebo (Woodcock 1981).
Benzodiazepines for breathlessness in cancer
Harrison (unpublished)
Twenty-six participants with advanced cancer were randomised
(cross-over), but only 17 participants completed the study and
were included in the analysis. Lorazepam 1.0 mg/day had no sta-
tistically significant effect on breathlessness at rest compared to
baseline and to placebo after five days of treatment. The result was
similar for the overall level of breathlessness, breathlessness at its
best, and breathlessness at its worst.
Navigante 2006
One hundred and one participants with terminal cancer were ran-
domised in a three-arm study with a parallel design that com-
pared midazolam 20 mg/day, morphine 10 mg/day, and midazo-
lam 20mg/day plus morphine 10 mg/day after 24 and 48 hours of
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treatment (plus rescue doses). Thirty-one participants died during
the study after receiving the treatment (no difference between the
study groups). Each treatment arm showed a statistically signifi-
cant reduction of breathlessness compared to baseline, but without
any differencewhen comparing the three arms after 48hours. After
24 hours, morphine only and the combination of both drugs were
slightly better than midazolam only. The highest percentage of
participants who experienced a relief of breathlessness (92%) was
in the midazolam plus morphine group after 24 hours; the lowest
percentage was in the midazolam-only group (46%). The mida-
zolam group reported the highest percentage of participants with
persistent and uncontrolled breathlessness after 48 hours (26%),
the midazolam plus morphine group the lowest.
For meta-analysis, we used the assessment after 48 hours unless
stated otherwise.
Navigante 2010
Sixty-three participants with advanced cancer were randomised
in a parallel design to compare midazolam 8 mg/day and mor-
phine 12 mg/day (control) over five days (starting doses with titra-
tion phase and rescue doses). Sixty-one participants completed the
study, with one drop-out in each group (31 participants in the mi-
dazolam group and 30 participants in the morphine group). Both
treatments showed a statistically significant reduction in breath-
lessness intensity after two, three, four, and five days compared
to baseline. Midazolam reduced breathlessness significantly better
than morphine when comparing the endpoints after all treatment
days. Twenty-one participants treated with midazolam reached a
50% reduction of breathlessness after the starting dose compared
to only 11 participants in the morphine group (P = 0.023). Ther-
apeutic failure was observed in 20% of participants in the mor-
phine group compared to none in the midazolam group. A dose
reductionwas necessary in one participant in themidazolam group
and in two participants in the morphine group due to excessive
somnolence.
For meta-analysis, we used the assessment after five days unless
stated otherwise.
Meta-analysis and summary
We could include all three studies of people with cancer in the
meta-analysis, but analysed the placebo-controlled and morphine-
controlled studies separately. The placebo-controlled study found
no statistically significant effect with a SMD of -0.06 (95% CI
-0.73 to 0.62) (Harrison (unpublished)) (Analysis 2.2). Pooling
of the two morphine-controlled studies also showed no statis-
tically significant effect, with a SMD of -0.68 (95% CI -2.21
to 0.84) (Navigante 2006; Navigante 2010) (Analysis 2.3). One
study demonstrated a statistically significant effect of midazolam
compared to morphine (Navigante 2010), but this result was con-
trary to a similar study by the same research group where the mor-
phine group showed a slightly better improvement of breathless-
ness than the midazolam group (Navigante 2006). We found no
difference when comparing midazolam withmidazolam plus mor-
phine (third study arm in Navigante 2006).
Overall, we found no statistically significant effect. Due to the high
level of heterogeneity in the designs of the three studies (control
group, study design, stage of disease, benzodiazepine, dose, and
route of application), the meta-analyses of all three studies should
be interpreted with caution. There are conflicting results in the
comparison of midazolam to morphine based on two studies from
the same research group.
Benzodiazepines for the prevention of episodic
breathlessness in cancer
Navigante 2006
The proportion of participants with episodic breathlessness was
lower in the midazolam plus morphine group (21.2/24.0%) than
in the morphine and midazolam groups after 24 and 48 hours,
and highest in the midazolam group (36.4/38.5%). The median
number of episodes of breathlessness per participant after 24 and
48 hours was higher in the morphine-only group (two episodes)
than in themidazolam-only andmidazolamplusmorphine groups
(one episode).
Navigante 2010
The proportion of participants with episodic breathlessness was
lower in the midazolam group compared to the morphine group
and reached a statistically significant level of P = 0.035 at three
days, P =0.034 at four days, and P< 0.001 at five days of treatment.
Meta-analysis and summary
We could include both studies that examined episodic breathless-
ness in the meta-analysis, comparing midazolam with morphine
in 116 and 108 participants with cancer, respectively, after 24 and
48 hours (Navigante 2006; Navigante 2010). For the second study
(Navigante 2010), we calculated the effect after 48 hours using the
measurement at the third day when asked about episodic breath-
lessness on the day before (that is 48 hours). Overall, we found
no statistically significant effect after 48 hours with a risk ratio of
0.76 (95% CI 0.53 to 1.09; 108 participants) (Analysis 4.3).
Although one study demonstrated a statistically significant positive
effect with midazolam after three, four, and five days (Navigante
2010), the previous study from the same research group observed
no difference between midazolam and morphine in preventing
episodic breathlessness.
Overall - benzodiazepines in breathlessness
Meta-analysis and summary
We excluded one study from the meta-analysis due to a lack
of methodological quality and lack of data (see Risk of bias in
included studies) (Eimer 1985). Therefore, we included seven
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studies in the overall meta-analysis of the review update and anal-
ysed placebo-controlled and morphine-controlled studies sepa-
rately. Pooling of the placebo-controlled studies showed no sig-
nificant effect with a SMD of -0.10 (95% CI -0.42 to 0.21)
(Harrison (unpublished); Man 1986; Shivaram 1989; Stege 2010;
Woodcock 1981) (Analysis 1.1; Figure 4). The meta-analysis of
all placebo-controlled studies included 156 observations equat-
ing to 78 participants. Pooling of the morphine-controlled studies
with 107 participants also showed no statistically significant effect
with a SMD of -0.68 (95% CI -2.21 to 0.84) (Navigante 2006;
Navigante 2010) (Analysis 1.2; Figure 5). Overall, there was no
statistically significant beneficial effect of benzodiazepines in the
relief of breathlessness at rest. These results must be interpreted
with caution due to the presence of heterogeneity among the seven
included studies regarding such components as disease group, con-
trol group, and benzodiazepine, among others.
Figure 4. Forest plot of comparison: 1 Overall, outcome: 1.1 Placebo-controlled/cross-over design.
Figure 5. Forest plot of comparison: 1 Overall, outcome: 1.2 Morphine-controlled/parallel design.
In the sensitivity analysis, a comparison to baseline of studies that
presented baseline and after-treatment measures demonstrated a
positive effect for benzodiazepines, but this did not reach statis-
tical significance (data not shown). However, changes from base-
line have a higher risk of confounders (for example regression to
the mean) compared to after-treatment measures and should be
avoided (Higgins 2011). Two studies looked at breathlessness on
exercise (Man 1986; Woodcock 1981), but we could not include
these in the meta-analysis due to a lack of appropriate data (data
presented only in graphs).
In summary, all but one study showed no beneficial effect of ben-
zodiazepines (Eimer 1985; Harrison (unpublished); Man 1986;
Navigante 2006; Shivaram 1989; Stege 2010). Only one study
showed a statistically significant effect of midazolam compared to
morphine (Navigante 2010), but as mentioned above this result
was in contrast to a previous study by the same research group
(Navigante 2006). One study demonstrated a beneficial effect
of diazepam, but this was not statistically significant (Woodcock
1981).
Secondary outcomes
Anxiety
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Four out of seven studies measured anxiety with different scales (
Eimer 1985;Harrison (unpublished);Navigante 2006;Woodcock
1981). Benzodiazepines did not reduce anxiety, either as a change
from baseline or compared to the control group after treatment.
Depression
Three studies examining depression found no statistically signif-
icant difference between the intervention and the placebo group
(Eimer 1985; Harrison (unpublished); Woodcock 1981).
Adverse effects
All studies assessed adverse effects, but Stege 2010 only reported
on respiratory adverse effects (none occurred). Two studies ob-
served no adverse effects (Eimer 1985; Shivaram 1989). Harrison
(unpublished) described three adverse effects in the intervention
group that lead to withdrawal compared to one case in the placebo
group. Man 1986 and Woodcock 1981 observed significantly
more adverse effects (mainly drowsiness) in the benzodiazepine
group compared to placebo. Navigante 2006 reported more ad-
verse effects (mainly somnolence) in the morphine group (19/45)
compared to midazolam (15/45). Surprisingly, the fewest adverse
effects were reported for the combination group (11/45; third arm
with midazolam plus morphine). The authors defined an adverse
effect as clinically relevant with Grade 2 to 4 (Grade 1 mild, 2
moderate, 3 severe, 4 life-threatening - but observed no Grade
4) and found the highest number in the morphine group (10/
16) compared to midazolam (3/16) and midazolam plus mor-
phine (3/16). These results were confirmed in the following study
(Navigante 2010), which found significantly more adverse effects
(mainly somnolence) in the morphine group compared to the mi-
dazolam group.
Regarding adverse effects, we observed a beneficial but not statis-
tically significant effect in the control group when studies used
placebo as a control (Analysis 5.1, Figure 6). Studies compar-
ing midazolam with morphine showed a statistically significant
favourable effect for midazolam (Analysis 5.2). Drowsiness and
somnolence were mainly reported with a statistically significant
difference between intervention and control group when placebo
was used as a control (benzodiazepines caused more drowsiness or
somnolence) (Analysis 5.4).
Figure 6. Forest plot of comparison: 5 Secondary outcomes, outcome: 5.1 Adverse effects (placebo-
controlled).
Exercise tolerance
Only three out of seven studies looked at breathlessness on exercise.
Eimer 1985 used a 12-minute walking distance test and Man
1986 used a 12-minute walking distance test and bicycle exercise.
They did not find any difference between benzodiazepines and
placebo regarding exercise tolerance. However, Woodcock 1981
demonstrated a significant impairment in walking distance after
12 minutes in the intervention group compared to placebo, and
a non-significant decline in time to exhaustion on treadmill and
workload on bicycle ergometer.
Quality of life
None of the included studies studied quality of life.
Attrition
Regarding attrition, there was no difference between the interven-
tion and control groups, either for the placebo-controlled stud-
ies or the morphine-controlled studies. Only one study reported
results in favour of the intervention group, with four dropouts
in the placebo group mainly due to increasing breathlessness and
drowsiness (Shivaram 1989). One study had no attrition, either
in the intervention or in the control group (Eimer 1985). One
study reported three dropouts: one participant was excluded from
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the intervention group due to an exacerbation of COPD dur-
ing the study, one participant was excluded due to obstructive
sleep apnoea-hypopnoea syndrome after baseline polysomnogra-
phy, and one withdrew due to burden of the measurements in
the control group (Stege 2010). One study reported five dropouts
(Man 1986); one dropout was assigned to the placebo group (un-
known adverse effect), and the other four dropouts were missing
appointments without assignment to one group. The Harrison
(unpublished) study reported twice as many dropouts in the
placebo group (six) as in the intervention group (three). Alterna-
tively, Woodcock 1981 counted twice as many dropouts in the
intervention group (two) as in the placebo group (one). The rea-
son for attrition was mainly drowsiness, which occurred in the
intervention group in both studies. Both dropouts in Navigante
2010 were missing follow-ups. Navigante 2006 had a very high
attrition rate, and all dropouts were due to death (31 deaths in all
three study arms with a total of 101 participants), but without a
difference when comparing the three arms. We could find no dif-
ference between intervention and control group regarding deaths
in all studies (Analysis 5.8; Analysis 5.9).
Others
Blood gases
Only one study reported a slightly but almost statistically sig-
nificant difference (P = 0.05) in blood gases between alprazolam
and placebo (PaO2 at rest higher and PaCO2 after exercise lower
with placebo) (Man 1986). All other studies that measured oxy-
gen saturation, PaO2, or PaCO2 found no significant change from
baseline or between intervention and control group (Eimer 1985;
Navigante 2006; Navigante 2010; Shivaram 1989; Stege 2010;
Woodcock 1981).
Spirometric tests
Only one study found a slightly but almost statistically significant
difference (P = 0.05) in spirometric tests with higher levels for
FEV1 (forced expiratory volume in one second), TLC (total lung
capacity), and FRC (functional residual capacity) in the placebo
group (Man 1986). Three other studies measured the functional
lung capacity, but did not find any significant change frombaseline
or between intervention and control group (Eimer 1985; Shivaram
1989; Woodcock 1981).
D I S C U S S I O N
Summary of main results
Benzodiazepines are widely used drugs in the treatment of breath-
lessness, but very few studies have evaluated their effectiveness.On
the basis of eight RCTs including 214 participants, we conclude
that there is no evidence for a beneficial effect of benzodiazepines
for the relief of breathlessness at rest in people with advanced can-
cer or chronic obstructive pulmonary disease (COPD). However,
this conclusion is based on a small number of studies with a lim-
ited number of participants, heterogeneity among included stud-
ies, and some inconsistency across the studies. Furthermore, we
could observe no statistically significant effect in the prevention
of episodic breathlessness in people with cancer. Sensitivity anal-
ysis demonstrated no statistically significant differences regarding
the type of benzodiazepine, dose, route and frequency of delivery,
duration of treatment, or type of control.
Overall completeness and applicability of
evidence
The study from Navigante 2010 is the only RCT that showed a
statistically significant beneficial effect, although it used morphine
as a control. This result is surprising, as morphine has been shown
to be effective in the relief of breathlessness (Jennings 2001). Fur-
thermore, a study from the same research group of people with
terminal cancer two years earlier demonstrated a contrary result,
with an advantage of morphine over midazolam, and best results
for the combination of the two drugs (Navigante 2006). However,
the results of the earlier study must be interpreted with caution as
there were some methodological difficulties: the authors studied
people with terminal cancer and observed a very high attrition
rate due to death (31/101); and they allowed rescue medication
during the study, therefore all three treatment arms might have
included both drugs and a valid differentiation of the effect was
not possible without uncertainty (Navigante 2006). Further stud-
ies are needed to examine the comparison between morphine and
midazolam and to verify the results of Navigante 2010.
Episodic breathlessnesswas only studied inpeoplewith cancer, and
the focuswas onpreventing breakthrough dyspnoea (no evaluation
of the effect on relief of episodic breathlessness) (Navigante 2006;
Navigante 2010). The extent of the beneficial preventative effect of
midazolam compared to morphine was larger after 48 hours than
after 24 hours, but statistically non-significant at both times. RCTs
assessing the treatment (not prevention) of episodic breathlessness
with benzodiazepines are still missing.
Most studies observed adverse effects. Drowsiness and somnolence
were mainly reported with a significantly higher occurrence in
the benzodiazepine group when a placebo was the control. In
contrast to the other studies, Shivaram 1989 reported attrition
only in the placebo group, due to increasing breathlessness and
drowsiness. We excluded these three cases from analysis. It could
be argued that the occurrence of increasing breathlessness only
in the placebo group favours the intervention group in the relief
of breathlessness, and this might have changed their conclusion.
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Shivaram 1989 argued that this could be a suggestive effect, as
participants were told that the treatment might cause increasing
breathlessness. However, as only 12 participants were included, it
is not possible to judge if this is a random effect.
There was no difference between the intervention and control
groups in respect to attrition and deaths, either for the placebo-
controlled studies or for the morphine-controlled studies. How-
ever, the reporting of dropouts in cross-over studies was not always
sufficient to assess when the dropout occurred (first or second pe-
riod of the study), in order to calculate the attrition (Eimer 1985;
Harrison (unpublished); Man 1986; Shivaram 1989; Stege 2010;
Woodcock 1981). Given the small numbers of dropouts, the po-
tential miscalculation is likely to be small for the present cross-
over studies. However, attrition must still be interpreted with cau-
tion. Navigante 2006 observed a high attrition rate due to deaths
(31/101) without any difference between the three study arms. As
mentioned before, all three treatment arms allowed a combination
of midazolam and morphine, therefore the high death rate could
not been attributed to a single drug. The authors argued that most
of the deaths were caused by the underlying advanced disease. As
they studied people with terminal cancer and a life expectancy of
less than a week, this seems likely. However, a relation between
treatment and death could not be excluded entirely because of
the relatively high doses of midazolam. There is some evidence
from a large cohort study that benzodiazepines alone might in-
crease mortality, but concurrent benzodiazepines and opioids do
not (Ekstrom 2014).
Different types of benzodiazepines were tested as well as differ-
ent doses, long- and short-acting drugs, and different durations
of treatment and modes of administration. However, we could
find no differences when conducting sensitivity analysis regarding
all these criteria. Furthermore, different comparators were used:
five studies used placebo (Harrison (unpublished); Man 1986;
Shivaram 1989; Stege 2010; Woodcock 1981), and two studies
usedmorphine as a control treatment (Navigante 2006; Navigante
2010). We therefore conducted separate meta-analyses for each
group with the same control treatment.
Themeasurement tools for examining breathlessness in all but one
study were validated and frequently used (Eimer 1985).
Quality of the evidence
Overall, this review analysed 214 participants in eight studies, in-
cluding 33 participants of the third intervention arm of the par-
allel-designed study from Navigante 2006. However, the num-
ber of participants in each single study was small (between five
and 35 in each comparison group). We intended to evaluate the
effect of benzodiazepines in five different disease groups (cancer,
COPD, chronic heart failure, motor neurone disease, and idio-
pathic pulmonary fibrosis), but could only identify studies of peo-
ple with COPD and cancer. Studies of the other patient groups
are also needed. One study identified in the review update in-
cluded people with different life-limiting diseases (seeHardy 2016
in Characteristics of studies awaiting classification section).
We judged seven out of eight studies to be of high quality on the
Edwards Method Score (15 or more on the scale) (Edwards 2003).
Tominimise the risk of bias, we excluded one study from themeta-
analysis due to lowmethodological quality (high risk of bias) based
on both the Edwards Method Score and the Cochrane ’Risk of
bias’ tool (Eimer 1985). However, the single-blinding process in
two studies (Navigante 2006; Navigante 2010), and the exclusion
of dropouts from analysis, increased the risk of bias in all stud-
ies. The ’Risk of bias’ tool also revealed that most studies were at
unclear risk regarding allocation concealment and potential attri-
tion bias (see “Risk of bias in included studies”) (Figure 3). The
Edwards Method Score has previously been used successfully for
judging the quality of non-pharmacological interventions (for ex-
ample communication sessions and treatments of breathlessness)
(Bausewein 2008; Edwards 2003). Our experience of using the
Edwards Method Score to assess the quality of a pharmacologi-
cal intervention in this review was good, however the tool seems
to overestimate the quality of studies compared to the Cochrane
’Risk of bias’ tool.
Potential biases in the review process
We combined cross-over trials and studies with a parallel design
in the meta-analysis and treated the cross-over studies as parallel
design. We did this after a critical analysis of all studies, review of
the literature (Elbourne 2002; Higgins 2011), discussion with a
statistician, and the following judgements:
1. the cross-over design was suitable for the targeted research
questions;
2. none of the cross-over studies showed evidence of a carry-
over effect;
3. dropouts were excluded from analysis;
4. there was no evidence for a period effect. This approach can
produce a unit-of-analysis error.
However, this error leads to a conservative analysis and under-
weighs the cross-over studies (Higgins 2011). Most cross-over
studies did not show an effect of benzodiazepines in the relief of
breathlessness. This conservative analysis therefore supports our
conclusion. In addition, sensitivity analysis showed no difference
when analysing the cross-over studies separately (Figure 4).
Two studies presented only median scores for post-treatment mea-
sures because of skewed data (Navigante 2006; Navigante 2010).
The mean and standard deviation (SD) was needed to include
these studies in the meta-analysis. Instead of calculating the mean
and SD from the median and range, we followed the advice of the
statistician of the Cochrane Pain, Palliative and Supportive Care
Review Group and obtained the mean and SD from the raw data
provided by the author. With this approach we were able to in-
clude these studies in the meta-analysis.
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Although we used a broad search strategy, we could have missed
some unpublished data, such as PhD or Masters theses. However,
we identified two unpublished studies through circular mails and
personal contact with authors in the original review (Harrison
(unpublished); Navigante 2010) (see Characteristics of ongoing
studies).
Agreements and disagreements with other
studies or reviews
Three excluded studies assessed breathlessness in healthy partic-
ipants and could not find a beneficial effect of diazepam (Jones
1985; Stark 1981a; Stark 1981b). The trial from Hosaka 1996
was the only study excluded because the participants were at non-
advanced disease stage (chronic respiratory insufficiency but lung
function tests above our inclusion criteria). This study was also
the only non-RCT study, but with a high risk of bias. A statis-
tically significant improvement in the relief of breathlessness was
seen in the intervention group in change from baseline. However,
baseline data between intervention and control groups were dif-
ferent. Othermethodological problems in this study (no wash-out
phase, breathlessness not primary outcome, sample of participants
included a few people with potentially curable disease) necessitate
careful interpretation of results. Apart from this trial, we identified
no study that looked at people with a non-advanced disease stage.
Furthermore, we included only RCTs in order to reduce the risk
of bias, but expected some uncontrolled trials in this area. Surpris-
ingly, we could only find one uncontrolled study (Greene 1989).
This case study reported a beneficial effect of alprazolam in one
participant. One excluded study was a single-site, open-label pi-
lot study of clonazepam together with sustained-release morphine
with 10 participants who completed the study showed promising
results (safety, feasibility) in order to justify a definitive phase III
study (Allcroft 2013).
After little research activity in this field, with a few studies in the
1980s and no studies during the 1990s, the set-up of four trials
during the last conduction of this review possibly offers hope for
further studies, which are urgently needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For the update of this review, we identified one additional study
for inclusion, but the conclusions remain unchanged.
• There is no evidence for a beneficial effect of
benzodiazepines in the relief of breathlessness in people with
advanced cancer and COPD. There is a non-significant beneficial
effect, but the overall effect size is small. Benzodiazepines caused
more drowsiness as an adverse effect compared to placebo but
less compared to morphine. These results justify considering
benzodiazepines as second- or third-line treatment, when opioids
and non-pharmacological measures have failed to control
breathlessness. Although we included a few low- to high-quality
studies in this review, there is still a further need for well-
conducted and adequately powered studies in this field.
• There is currently not enough evidence to support the use
of benzodiazepines in the prevention of episodic breathlessness in
people with cancer. There are no data from controlled trials for
the treatment of episodic breathlessness with benzodiazepines.
• There are no differences regarding the type of
benzodiazepine, dose, mode and frequency of administration,
and duration of treatment.
Implications for research
Although we included a few high-quality studies in this review,
there is still a further need for more well-conducted and larger
studies in this field. Further research should pay attention to the
following issues.
• Larger studies with more participants to reach a statistically
sound conclusion are required.
• More attention should be paid to the reporting of
methodological details of randomised controlled trials because
this is essential for interpretation of the results.
• Studies in chronic heart failure (CHF), motor neurone
disease (MND), idiopathic pulmonary fibrosis (IPF), and other
life-threatening diseases with breathlessness (e.g. advanced renal
failure) are needed.
• Treatment of episodic breathlessness with benzodiazepines
has not yet been studied in controlled trials.
• Benzodiazepines in the relief of breathlessness with panic
attacks might be worth studying.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Eimer 1985
Methods Design: RCT, cross-over, placebo-controlled
Blinding: double
Methodological quality: 10/22 (Edwards Method Score)
Participants Disease: COPD
Number (randomised): N = 5
Setting: hospital
Age (years, mean): not stated (only range: 51 to 68)
Sex (male/female): 4/1
Participant pool: 56
Randomised: 5; study completed: 5
Withdrawals/dropouts: 0 (intervention 2 (clorazepate 22.5 mg) with 3 dropouts; whole
intervention excluded from analysis)
Reason for drop-out (intervention 2): intolerable AEs (which AEs not mentioned)
Baseline parameters: FEV1 less than 50%
SpO2 (mmHg): 65.36; SpCO2 (mmHg): 41.58
Interventions Drug (dose): 1. clorazepate (7.5 mg) at bedtime; 2. clorazepate (22.5) mg at bedtime; 3.
placebo
Delivery: oral
Duration of treatment: 2 weeks
Outcomes Breathlessness grade (1 to 6)
Results: no significant difference between clorazepate and placebo regarding dyspnoea
and walking test (no numbers given; dyspnoea change only in graphs)
Adverse effects: none within the 5 participants in intervention 1 and placebo
SpO2 and SpCO2: no significant change
Notes Author conclusion: this study failed to demonstrate that placebo or clorazepate consis-
tently relieved breathlessness in non-anxious people with severe COPD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not mentioned
(“Patients were assigned in a randomised
double-blind manner”)
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blinding stated in the abstract, but
not mentioned further
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Eimer 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned
Selective reporting (reporting bias) High risk Anxiety, depression, etc. were assessed but
data not reported
Other bias High risk • Inclusion criterion “severe COPD”
not explained (although the results of
COPD functions did meet our inclusion
criteria)
• No literature/validity regarding
dyspnoea grading
• Lack of participant demographics
(only gender and age range)
• Imbalance in male/female (4/1)
• No reasons for exclusion after
screening
• Not clearly mentioned that
“treatment” means “7.5 mg clorazepate”
(conclusion made only after a statement
that 22.5 mg group was excluded due to
attrition)
• Results, especially for dyspnoea,
poorly presented and difficult to read
• Data have been presented only in a
graph describing “improvement” or
“worse” compared to baseline after first
and second week of intervention or
placebo
• Numbers are only approximate,
because it is difficult to read them in the
graph
Harrison (unpublished)
Methods Design: RCT, cross-over, placebo-controlled
Blinding: double-blind
Methodological quality: 18/22 (Edwards Method Score)
Participants Disease: advanced cancer (12/17 lung cancer)
Number (randomised): N = 26
Setting: outpatient and inpatient
Age (years, SD): 67.2 (8.3)
Sex (male/female): 16/1
Participant pool: 54
Randomised: 26; study completed: 17
Withdrawals/dropouts: 9 (4 drowsiness, 1 deterioration, 1 dysphagia, 2 death, 1 unclear)
(excluded from analysis)
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Harrison (unpublished) (Continued)
Interventions Drug (dose): lorazepam (0.5 mg twice daily = 1 mg per day)
Delivery: oral
Duration of treatment: 5 days (2 days wash-out)
Outcomes Dyspnoea VAS 0 to 100 (“How much trouble has your breathing caused you over the
last 24 hours?”)
Results (mean): baseline to 5 days after intervention: 1. lorazepam 49.18 to 44.49; 2.
placebo 48.06 to 45.94
Adverse effects (number of AEs/number with withdrawals): 1. lorazepam: 5/3; 2 placebo:
4/1
No change or differences in anxiety and depression (HADS)
Notes Author conclusion: there were no differences between lorazepam and placebo in relieving
breathlessness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...was randomly determined by computer
prior to the study commencement”
Allocation concealment (selection bias) Low risk “A randomisation list was kept by the phar-
macy”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data were presented
The study author sent the raw data in ad-
dition
Selective reporting (reporting bias) Low risk Study protocol is available
Other bias Low risk Study appeared to be free of other bias
Man 1986
Methods Design: RCT, cross-over, placebo-controlled
Blinding: double
Methodological quality: 16/22 (Edwards Method Score)
Participants Disease: COPD
Number (randomised): N = 29
Setting: outpatient
Age (years, mean): 65.4
Sex (male/female): 16/8 (complete)
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Man 1986 (Continued)
Participant pool: not stated
Randomised: 29; study completed: 24
Withdrawals/dropouts: 5 (excluded from analysis)
Reason for drop-out: 1 AE (placebo), 4 missed appointments
Baseline parameters: FEV1/FVC: 54%
SpO2 (mmHg): 73.4; SpCO2 (mmHg): 32.8
Interventions Drug (dose): alprazolam 1.0 mg/day (0.5 mg twice daily)
Control: placebo
Delivery: oral
Duration of treatment: 1 week
Outcomes Dyspnoea grade at rest (1 to 5); dyspnoea scoring at rest and exercise (VAS 0 to 10)
Results (mean, baseline to after intervention): alprazolam: 3.0 to 3.0; placebo: 3.2 to 3.
0
No significant change in dyspnoea scoring during rest and exercise
Adverse effects: 11 reported (7/11 drowsiness), 9/11 on alprazolam
Functional test (12-minute walking test in metres; baseline to after intervention): alpra-
zolam: 896.5 to 880.88; placebo: 902.17 to 931.29
The resting SpO2 was significantly higher with placebo and exercising SpCO2 was sig-
nificantly lower with placebo
Notes Author conclusion: the subjective perception of dyspnoea was the same before and after
alprazolam, at rest and during exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...designed as a randomized...”
Not mentioned how this was done
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind...using alprazolam and
matching placebo”
Labelled bottles with tablets (alprazolam-
placebo-wash-out) described in detail
Probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Total screened patients not mentioned
No intention-to-treat analysis (5/29 lost
were excluded from analysis), however only
one with AE (placebo)
Selective reporting (reporting bias) Low risk Broad information available, good sum-
maries, good presentation
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Man 1986 (Continued)
Other bias Low risk Pharmaceutical funding (company with al-
prazolam), although negative results
Navigante 2006
Methods Design: RCT, parallel, multi-arm (3), control: morphine and morphine + midazolam
Blinding: single-blind (only participant blinded)
Methodological quality: 17/22 (Edwards Method Score)
Participants Disease: terminal cancer (life expectancy less than a week)
Number (randomised): N = 101
Setting: hospital inpatient
Age (years, mean): 57.3
Sex (male/female): 47/54
Participant pool: n = 146
Randomised: 101; study completed: 70
Withdrawals/dropouts: 31 (all deaths) (excluded from analysis)
Interventions Drug (dose): 1. morphine (Mo - 10 mg/day); 2. midazolam (Mi - 20 mg/day); 3.
morphine + midazolam (MM - Mo 10 mg/day + Mi 20 mg/day)
Rescue dose: 1. Mi 5 mg; 2. Mo 2.5 mg; 3. Mo 2.5 mg (this means that all 3 treatment
arms could include a combination of morphine and midazolam)
Delivery: subcutaneous
Duration of treatment: 48 hours
Outcomes Dyspnoea intensity: modified Borg scale 0 to 10
Results presented in the paper: baseline (mean) to after intervention (24/48 hours =
median and P-values): 1. (Mo) 7.1 to 3/2 (P=0.002/P=0.0001); 2. (Mi) 6.9 to 4/2 (P=
0.018/P=0.004); 3. (MM) 6.8 to 3/2 (P=0.003/P<0.0001)
(Mean and CI (95%) for 24- and 48-hour measures received from the authors (data
skewed): 1. (Mo) 24 hours: 3.9 (2.8 to 5.0), 48 hours: 2.8 (1.6 to 4.0); 2. (Mi) 24 hours:
4.1 (2.8 to 5.4), 48 hours: 3.1 (1.7 to 4.5); 3. (MM) 24 hours: 3.4 (2.4 to 4.4), 48 hours:
3.0 (2.0 to 4.0))
Percentages of participants with breakthrough dyspnoea (24/48 hours): 1. (Mo) 34.3%/
38%; 2. (Mi) 36.4%/38.5%; 3. (MM) 21.2%/24%
Numbers of breakthrough episodes of dyspnoea per participant (24/48 hours): 1. (Mo)
2/2; 2. (Mi) 1/1; 3. (MM) 1/1
Percentages of participants with dyspnoea relief after 24 hours: 1. (Mo) 69% (P=0.03);
2. (Mi) 46% (P=0.004); 3. (MM) 92% (P-values compare to MM)
Percentages of participants with persistent, uncontrolled dyspnoea after 48 hours: 1.
(Mo) 12.6%; 2. (Mi) 26% (P=0.04 compare to MM); 3. (MM) 4%
Adverse effects: the most frequently recorded AE was somnolence (Mo > MM > Mi)
Oxygen saturation (mean; baseline to after intervention; 24/48 hours): 1. (Mo) 72% to
72%/70%; 2. (Mi) 73% to 70%/70%; 3. (MM) 73% to 73%/71.5%
Anxiety: significant correlation between dyspnoea and anxiety at all times
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Navigante 2006 (Continued)
Notes Author conclusion: the data demonstrate that the beneficial effects of morphine in con-
trolling baseline levels of dyspnoea could be improved with the addition of midazolam
to the treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...using a random number generator in 1:
1:1 ratio in blocks of nine”
Allocation concealment (selection bias) Unclear risk Not mentioned how it was done
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Drug administrations were performed in
a single-blind fashion.”
“One potential limitation of our study is
the single-blindednature of the design.The
treating physicians’ knowledge of which
schedule of drugs the patient received could
influence their need for administering res-
cue medications. A double-blind design
can avoid this, but was considered not ap-
propriate for our study population by the
Ethics Committee at our institution. Nev-
ertheless, the risk for underestimation of
rescue needs was minimized by a double as-
sessment of breakthrough episodes carried
out by caregivers and research physicians.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 45/146 excluded with statement of reasons
Attrition (deaths) clearly mentioned
Missing data not stated
Unclear if participants who experienced re-
lief of dyspnoea was assessed on the whole
number of participants or only on partic-
ipants alive at the end of the study (30%
died)
Selective reporting (reporting bias) High risk Unclear which other symptoms were mea-
sured (only anxiety-dyspnoea is reported).
Results of ECOG andMMSE not reported
Dyspnoea relief (only after 24 hours)
and uncontrolled dyspnoea (only after 48
hours)
Other bias High risk Using cross-over rescue medication (mida-
zolam for the morphine group and vice
versa) could produce confusion for separate
analysis
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Navigante 2010
Methods Design: RCT, parallel, control: morphine
Blinding: single-blind (only participant and caregiver blinded)
Methodological quality: 21/22 (Edwards Method Score)
Participants Disease: advanced cancer
Number (randomised): N = 63
Setting: outpatient clinic
Age (years, median, intervention group 1/2): 59/55
Sex (male/female): not mentioned
Participant pool: not mentioned
Randomised: 63; study completed: 61*
Withdrawals/dropouts: 2* (unable or unwilling to comply with the programmed follow-
up visits) (excluded from analysis)
*Data at day 5 for the morphine group were only available for 29 participants, therefore
all calculations at day 5 were done with 29 participants
Interventions Drug (starting dose within fast titration phase): 2 mg for oral midazolam or 3 mg for
oral morphine with incremental steps of 25% of the preceding dose every 30 min until
dyspnoea was alleviated 50% or more (“effective dose” used in follow-up assessment)
Delivery: oral
Duration of follow-up treatment: 5 days using the “effective dose” every 4 hours (except
the sleep hours)
Outcomes Dyspnoea relief (fast titration phase): 5-category scale (0% none, 25% slight, 50%
moderate, 75% a lot, 100% complete)
Dyspnoea intensity for the chronic component of dyspnoea (baseline and follow-up
assessment): NRS 0 to 10
Proportion of participants with BTD episodes
Number of BTD episodes per day
Results presented in the published paper:
In the fast titration phase dyspnoea relief of at least 50% was achieved in all participants
in both arms (after starting dose: midazolam 21/32 vs morphine 11/31 (P = 0.023), after
dosing step 1: 9/32 vs 11/31 (P = 0.59), and after dosing step 2: 2/32 vs 9/31 (P = 0.
022)); in the follow-up phase, mean (95% CI) baseline dyspnoea intensity is presented
in a table: midazolam 8.8 (±0.3) vs morphine 8.7 (±0.3) (P = 0.62), but follow-up results
on dyspnoea intensity are only presented in figure with box plots (participants receiving
midazolam maintained a significantly lower dyspnoea intensity level in comparison with
the morphine group, during the 4 days of follow-up) and as median at the second day
in text: midazolam 6 vs morphine 4.5 (P = 0.003);
number of participants with 1 or more BTD episodes at baseline was 25 in both arms,
and the proportion of participants with BTD episodes was significantly different at days
3 to 5, favouring the midazolam arm (data only presented by a figure);
therapeutic failure (i.e. NRS 8 to 10 by day 5) midazolam 0/31 vs morphine 6/30;
AE (n during fast titration phase): mild somnolence midazolam 18/32 vs morphine 15/
31, mild agitation 2/32 vs 2/31, mild and moderate nausea only morphine 2/31 and 1/
31;
AE (n during follow-up): somnolence (time spent sleeping during daytime) 3 h to 5
h midazolam 4/31 vs morphine 5/30, 6.11 h only morphine 1/30; agitation grade 1/2
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Navigante 2010 (Continued)
only in morphine arm 2/1/30; nausea grade 1 only morphine 1/30; constipation grade
2 only morphine 2/30; others midazolam 1/31 (cognitive disturbance) vs morphine 2/
31 (cough g1, pruritus g2, xerostomia g1, flushing g1);
dose reduction (because of excessive somnolence): midazolam 1 vs morphine 2;
Oxygen saturation: no change in either group
Additional results received from the authors:
Mean (95% CI) dyspnoea intensity for baseline and day 5 measures (data skewed): 1.
(midazolam) baseline: 8.84 (8.50 to 9.19), day 5: 3.23 (2.51 to 3.94); 2. (morphine)
baseline: 8.74 (8.44 to 9.04), day 5: 6.00 (5.31 to 6.69)
Notes Author conclusion: the data demonstrate the beneficial effect of midazolam versus mor-
phine in the relief of chronic dyspnoea intensity and the number of episodes of breath-
lessness (breakthrough dyspnoea), while adverse events occurred and were comparable
between both arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random number generator in 1:1 ratio in
blocks of six”
Allocation concealment (selection bias) Low risk “Numbered envelopes that were used to
implement the randomization were con-
cealed until interventions were assigned.
The researchers had final responsibility for
patient enrollment”
Blinding (performance bias and detection
bias)
All outcomes
High risk Only single-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on dealing with missing
data or presence of it
Selective reporting (reporting bias) Low risk No indication of selective reporting
Other bias Unclear risk None
Shivaram 1989
Methods Design: RCT, cross-over, placebo-controlled
Blinding: double
Methodological quality: 15/22 (Edwards Method Score)
Participants Disease: COPD
Number (randomised): N = 12
Setting: unclear
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Shivaram 1989 (Continued)
Age (years, mean): 64.9
Sex (male/female): 8/0
Participant pool: not stated
Randomised: 12; study completed: 8
Withdrawals/dropouts: 4 (excluded from analysis)
Reason for drop-out: all on placebo (3/4 increasing dyspnoea and drowsiness, 1/4 acute
exacerbation)
Baseline parameters: FEV1/FVC: all less than 65%
SpO2 (mmHg): 76.0; SpCO2 (mmHg): 38.0
Interventions Drug (dose): alprazolam 0.75 mg/day (0.25 mg 3 times a day)
Control: placebo
Delivery: oral
Duration of treatment: 2 weeks
Outcomes Dyspnoea (modified Borg scale 0 to 10)
Results* (baseline to after intervention): alprazolam: 3.6 to 3.6; placebo: 3.6 to 3.0 (*not
explicitly stated if mean or median, but must be mean because of decimal numbers)
Adverse effects: none within the 8 participants
SpO2 and SpCO2: no significant change
Notes Author conclusion: alprazolam did not alter the sensation of breathlessness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were started on a double-blind,
randomized crossover regimen”
“The patients then received either placebo
or alprazolam 0.25 mg in a double-blind
fashion”
Not mentioned how this was done
Allocation concealment (selection bias) Unclear risk Not mentioned how it was done
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The medication code was known only to
the hospital pharmacist.”
“Patients were started on a double-blind,
randomized crossover regimen”
“The patients then received either placebo
or alprazolam 0.25 mg in a double-blind
fashion”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Described the attrition and reasons for it
Excluded fromanalysis, but stated that they
did not differ with regard to spirometric
measures
Demographics only from included partici-
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Shivaram 1989 (Continued)
pants (8/12)
No predicted FEV1 and FVC mentioned
Selective reporting (reporting bias) Low risk No indication for selective reporting
Other bias High risk Only men (Veterans Affairs Medical Cen-
ter)
Stege 2010
Methods Design: RCT, placebo-controlled, cross-over design
Blinding: double
Methodological quality: 16/22 (Edwards Method Score)
Participants Disease: COPD (stages III to IV)
Number (randomised/analysed): n = 17/14
Setting: outpatient center of a respiratory medicine department
Age (years, mean, SD): 61.6 8.0
Sex (male/female): 10/4
Participant pool: 199
Randomised: 17; study completed: 14
Withdrawals/dropouts: 3 (excluded from analysis)
Reason for drop-out: 1/3 on intervention: (exacerbation of COPD), 2/3 on placebo
(1 obstructive sleep apnoea-hypopnoea syndrome, 1 withdrew due to burden of the
measurements)
Baseline parameters: FEV1/FVC (mean, SD) 32.7 13, PaCO2, kPa 5.4 0.4, PaO2,
kPa 9.6 0.7
Baseline sleep-related complaints: difficulty maintaining sleep (experienced by 8 partic-
ipants), a prolonged sleep-onset latency (experienced by 7 participants), extensive day-
time sleepiness (experienced by 6 participants), and nocturnal dyspnoea (experienced by
2 participants)
Baseline medication: inhaled corticosteroids 14/14, anticholinergics 13/14, β2-antago-
nists 9/14, oral steroids 4/14, proton pump inhibitors 4/14, anticoagulants 4/14, other
antihypertensives 4/14, theophylline 3/14, diuretics 3/14, acetylcysteine 1/14
Interventions Drug (dose): temazepam 10 mg/day (30 min before bedtime)
Control: placebo
Delivery: oral
Duration of treatment: 1 week each, with 1-week wash-out time
Outcomes Subjective dyspnoea (10-point VAS)
Results (mean (SD)): subjective dyspnoea: baseline 3.8 (2.6), temazepam 4.2 (2.9),
placebo 4.1 (2.5), P = 0.90;
transcutaneous carbon dioxide (PtcCO2) during sleep: baseline 6.2 (0.6), temazepam 5.
9 (1.0), placebo 6.3 (1.4), P = 0.27; oxygen saturation (SpO2) during sleep: baseline 92
(2), temazepam 92 (3), placebo 92 (2), P = 0.31;
total sleep time, h (mean (SD)): baseline 5.7 (1.2), temazepam 6.3 (1.0), placebo 5.4 (1.
1), P = 0.03;
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Stege 2010 (Continued)
sleep latency (10-point VAS): baseline 4.4 (3.2), temazepam 3.3 (2.8), placebo 4.6 (3.
2), P = 0.03;
amount of stage 2 sleep, minutes (non-rapid eye movement sleep): baseline 130.8 (54.
5), temazepam 168.8 (34.4), placebo 140.0 (44.6), P = 0.03;
no statistically significant changes for the other secondary outcomes;
Adverse effects: none reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were randomized after the
baseline measurements to use 10 mg
temazepam or placebo once a day orally,
both during one week, separated by a
washout-period of one week. (...) Random-
ization was done by the hospital pharmacy.
”
Not mentioned of how this was done
Allocation concealment (selection bias) Unclear risk “Subjects were randomized after the
baseline measurements to use 10 mg
temazepam or placebo once a day orally,
both during one week, separated by a
washout-period of one week. Randomiza-
tion was done by the hospital pharmacy.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Subjects were randomized after the
baseline measurements to use 10 mg
temazepam or placebo once a day orally,
both during one week, separated by a
washout-period of one week. Randomiza-
tion was done by the hospital pharmacy.
Subjects were instructed to take the study
medication30minbefore theywent to bed.
(…) Sleep was manually staged according
to standard methods by two qualified sleep
technicians blinded to the subject’s treat-
ment status.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Described the attrition (3/17) and the rea-
sons for it, but did not describe participant
characteristics of dropouts. No intention-
to-treat analysis (14 of 17 enrolled partici-
pants analysed)
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Selective reporting (reporting bias) Unclear risk The article addresses only respiratory ad-
verse events; it is unclear if other than res-
piratory events had occurred
Other bias Unclear risk • Lack of participant characteristics (e.
g. no information on comorbidity,
functional status)
• More male than female participants
• No control for specific participant
characteristics or medication, no
sensitivity analysis
• The stability of the COPD was not
objectively confirmed with spirometry at
the second week, but only assessed on
clinical grounds
• Small sample size limits
interpretation of secondary endpoints
(including breathlessness intensity)
Woodcock 1981
Methods Design: RCT, cross-over, placebo-controlled, multi-arm (3)
Blinding: double
Methodological quality: 15/22 (Edwards Method Score)
Participants Disease: COPD
Number (randomised): N = 18
Setting: outpatient
Age (years, mean): 60.5
Sex (male/female): 15/3
Participant pool: not stated
Randomised: 18; study completed: 15
Withdrawals/dropouts: 3 (excluded from analysis)
Reason for drop-out: 1 death (diazepam), 1 intolerable drowsiness (diazepam), 1 hyper-
capnia (placebo)
Baseline parameters: FEV1: 25.3%; FEV1/FVC: 0.38
SpO2 (kPa): 9.5 (= 71.25 mmHg); SpCO2 (kPa): 4.6 (= 34.5 mmHg)
Interventions Drug (dose): 1. diazepam 25 mg/day (5 mg 3 times a day plus 10 mg at bedtime); 2.
promethazine 125 mg/day (25 mg 3 times a day plus 50 mg at bedtime); 3. placebo
Delivery: oral
Duration of treatment: 2 weeks
Outcomes Dyspnoea grade (1 to 5) after each intervention and daily dyspnoea by VAS (0 to 10) at
rest and after exercise (only by graph)
Results (mean): dyspnoea grade: 1. 3.46 (diazepam); 2. 3.29 (P < 0.05) (promethazine)
; 3. 4.00 (placebo)
Adverse effects (6 - reduce dosage): all drowsiness: 5/6 diazepam; 1/6 promethazine; 5/
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5 drowsiness incidents (like falling down stairs) with diazepam
Functional test (12-minute walking test in metres): 1. 642 (P < 0.05) (diazepam); 2. 707
(P < 0.05) (promethazine); 3. 675 (placebo)
SpO2 and SpCO2: no significant change
No significant change in anxiety and depression
Notes Author conclusion: diazepam had no significant effect on breathlessness and noticeably
reduced exercise tolerance. Promethazine reduced breathlessness and improved exercise
tolerance without altering lung function
Review author: however, there is a beneficial effect of diazepam, although not significant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The treatments were given in a random-
ized order.”
Not mentioned how this was done
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind” procedure was described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although 3/18 participants were lost and
excluded from the analysis, they would un-
derline the presented results rather than
bias them
Selective reporting (reporting bias) Unclear risk All main outcomes are presented in detail
The effect of diazepam in the relief of
breathlessness is nearly statistically signifi-
cant, but was discussed as “diazepam had
no effect on breathlessness”
Other bias Unclear risk It is not explicitly stated if a wash-out phase
was used (on contacting the author, there
was no wash-out)
Results of compliance test are not men-
tioned
Screening method and numbers are not
mentioned
AEs = adverse effects
BTD = breakthrough dyspnoea
CI = confidence interval
COPD = chronic obstructive pulmonary disease
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ECOG = Eastern Cooperative Oncology Group
FEV1 = forced expiratory volume in one second
FVC = forced vital capacity
HADS = Hospital Anxiety and Depression Scale
Mi = midazolam
MM = midazolam + morphine
MMSE = Mini-Mental State Exam
Mo = morphine
NRS = numeric rating scale
RCT = randomised controlled trial
SD = standard deviation
VAS = visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allcroft 2013 Non-controlled study (phase II)
Allen 1984 Review
Anonymous 1980a Review
Anonymous 1980b Review
Appel 1989 No subjective measurement of breathlessness; different drug (flumazenil)
Argyropoulou 1993 Different drug (buspirone)
Bar-Or 1982 Review
Beaupre 1988 No subjective measurement of breathlessness
Borson 1992 Different drug (nortriptyline)
Bottomley 1990 No subjective measurement of breathlessness; observational design
Boyden 2015 Systematic review
Catchlove 1971a No subjective measurement of breathlessness
Catchlove 1971b No subjective measurement of breathlessness
Cherny 2014 Guideline
Clark 1971 No subjective measurement of breathlessness; case series
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Clemens 2011 Non-controlled study (before-after design)
Cohn 1992 No subjective measurement of breathlessness
Daubert 2014 Study protocol; study was cancelled before any participants were enrolled
De Sousa 1988 No subjective measurement of breathlessness; letter/observational design
Denaut 1974 No subjective measurement of breathlessness
Dolly 1982 No subjective measurement of breathlessness; healthy participants
Dowson 2004 Review
Ekstrom 2015 Review
Fonsmark 2015 Guideline
Forster 1983 No subjective measurement of breathlessness; healthy participants
Gaddie 1972 Review
Garrett 2015 Review
Geddes 1976 No subjective measurement of breathlessness
Gomutbutra 2013 Non-controlled, retrospective study
Greene 1989 Non-controlled experimental study (case report)
Guilleminault 1993 No subjective measurement of breathlessness; observational design
Guz 1980 Review
Heinonen 1972 No subjective measurement of breathlessness; sedation for artificial ventilation
Hoeijer 1994 No subjective measurement of breathlessness; different disease (sleep apnoea)
Horfarter 2006 Review
Hosaka 1996 Non-advanced disease stage; a few participants with a different disease (asthma, tuberculosis)
Huttemann 1971 Different drug (laevomepromazine)
Johanson 1993 Review
Jokinen 1984 Different disease (psychosomatic disorder)
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Jolly 1996 No subjective measurement of breathlessness; observational design
Jones 1985 Different disease (healthy participants)
Kaltsas 2014 Editorial
Kann 1968 Review
Kronenberg 1975 No subjective measurement of breathlessness; observational design
Lakshminarayan 1976 No subjective measurement of breathlessness; healthy participants
Lareau 1999 No drug intervention (secondary analysis)
Laros 1982 No subjective measurement of breathlessness; case report; no benzodiazepine
Lichterfeld 1967 Benzodiazepine only in combination (oxazepam + orciprenaline)
Light 1996 Different drug (promethazine)
Marin 1987 No drug intervention (retrospective study)
McIver 1994 Different drug (chlorpromazine)
Mitchell-Heggs 1980a No subjective measurement of breathlessness; no control group; no standardised or systematic design
Mitchell-Heggs 1980b No drug intervention
Mouzi 2014 No subjective measurement of breathlessness; case report
Murciano 1990 No subjective measurement of breathlessness
Murciano 1993 No subjective measurement of breathlessness
Navigante 1997 Benzodiazepine only in combination (midazolam + morphine)
Navigante 2003 Benzodiazepine only in combination (midazolam + morphine)
NCT01687751 Study failed to recruit any participants
Nordt 1997 Review
O’Donnell 1992 No drug intervention (observational study)
O’Donnell 1994 Review
O’Donnell 1998 Review
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O’Neill 1985 Different drug (chlorpromazine)
Rao 1973 No subjective measurement of breathlessness
Rapoport 1991 No subjective measurement of breathlessness; healthy participants
Rice 1986 Review
Rice 1987 Different drug (promethazine)
Rodriguez-Roisin 2014 Editorial
Rose 2002 Review
Rudolf 1978 No subjective measurement of breathlessness
Runo 2001 Review
Schultze-Werninghaus 2007 Review
Sen 1983 No subjective measurement of breathlessness; no control group
Singh 1993 Different drug (promethazine)
Smith 2015 Review
Stark 1981a Different disease (healthy participants)
Stark 1981b Different disease (healthy participants)
Stark 1983 Different drug (dihydrocodeine)
Stark 1988 Review
Steens 1993 No subjective measurement of breathlessness
Tenorio 2012 Non-controlled, retrospective study; congress abstract
Timms 1988 No subjective measurement of breathlessness
Vozoris 2013 Observational design
Walsh 1993 Review
Wanrooij 2005 Review
Wiedemann 1995 Review
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Wilson 1954 No subjective measurement of breathlessness; different drug (oxygen, morphine, barbiturate)
Woodcock 1981a Different drug (dihydrocodeine, alcohol, caffeine)
Woodcock 1981b Different drug (oxygen)
Characteristics of studies awaiting assessment [ordered by study ID]
Hardy 2016
Methods Design: multicentre, placebo-controlled, cross-over design, blinded (masking used) RCT
Participants Inclusion criteria: adults with dyspnoea related to life-limiting disease (malignant and non-malignant) or its treatment,
dyspnoea score > 3/10 on at least 3 occasions during the previous week, English speaking or have an interpreter
available, AKPS scale > 30, able to operate a nasal spray device, able to understand all trial requirements and complete
a dyspnoea diary, no changes in any medication likely to affect dyspnoea (e.g. steroids, opioids) within 48 hours of
starting the study
Target sample size: 200 > terminated after interim analysis including 75 participants
Interventions Intranasal midazolam (3 inhalations (total dose of 1.5 mg active drug) vs placebo (citric acid 7.65 mg/ml in normal
saline placebo nasal spray)
Outcomes Primary outcome: dyspnoea intensity at 15 minutes compared to baseline
Secondary outcomes: DID (dyspnoea intensity difference) at 5, 30, and 60 mins, sedation (NRS 0 = not at all drowsy
to 10 = extremely drowsy), anxiety (NRS 0 = not at all anxious to 10 = extremely anxious)
Notes The study has been published just before publication of this review update
The study is registered at the Australian New Zealand Clinical Trials Registry (ACTRN), trial ID: AC-
TRN12609000506291, Title: Midazolam nasal spray for the treatment of breathlessness in patients with life-limiting
disease
Contact information: Clare Randall, Arohanui Hospice 1 Heretaunga St Palmerston North 4414, New Zealand,
clare.r@arohanuihospice.org.nz
Hart 2012
Methods Design: randomised, double-blind, double-dummy, placebo-controlled pilot study
Participants 30 people with severe respiratory disease (MRC dyspnoea score 4 or 5)
Interventions Lorazepam tablets 0.5 mg twice daily with dummy nasal spray up to 4 times daily or intranasal midazolam (dose 400
mg) 2 sprays up to 4 times daily with placebo tablets
Outcomes Primary outcome measures were designed to evaluate quality of life measures incorporating change in:
• Borg score whilst on treatment
• St. George’s Respiratory Questionnaire (SGRQ) score
• Hospital Anxiety and Depression Scale (HADS) scores
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• Nottingham Activities of Daily Living (NADL) score
Notes The authors conclude in the abstract that intranasal midazolam is no less effective in this setting than oral lorazepam
and suggest that intranasal midazolam is another useful tool for managing dyspnoea. However, only conference
abstract is available; we contacted two of the authors asking for further details, but did not receive an answer until
the review was published
AKPS = Australia-modified Karnofsky Performance Status
DID = dyspnoea intensity difference
MRC = Medical Research Council
NRS = numeric rating scale
RCT = randomised controlled trial
48Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Overall
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Placebo-controlled/cross-over
design
5 156 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.42, 0.21]
2 Morphine-controlled/parallel
design
2 107 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-2.21, 0.84]
Comparison 2. Disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 COPD 4 122 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.52, 0.29]
2 Cancer - placebo-controlled 1 34 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.73, 0.62]
3 Cancer - morphine-controlled 2 107 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-2.21, 0.84]
Comparison 3. Intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Benzodiazepines - alprazolam 2 64 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.41, 0.57]
2 Benzodiazepines - diazepam 1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.72 [-1.46, 0.02]
3 Benzodiazepines - midazolam 2 107 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-2.21, 0.84]
4 Benzodiazepines - temazepam 1 28 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.91, 2.11]
5 Benzodiazepines - ultra
short-acting
2 107 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-2.21, 0.84]
6 Benzodiazepines -
intermediate-acting
4 126 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.31, 0.38]
7 Benzodiazepines - long-acting 1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.72 [-1.46, 0.02]
8 Benzodiazepines - short duration
of treatment (
<
= 24 hours)
2 116 Std. Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.74, 0.01]
9 Benzodiazepines - long duration
of treatment (5 to 14 days)
5 156 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.42, 0.21]
10 Benzodiazepines - morphine +
midazolam-controlled
1 46 Std. Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.54, 0.61]
11 Benzodiazepines -
promethazine-controlled
1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.72, 0.72]
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Comparison 4. Primary outcome
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Breathlessness - no relief
(placebo-controlled)
2 50 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.56, 1.39]
2 Breathlessness - no relief
(morphine-controlled)
1 55 Risk Ratio (M-H, Random, 95% CI) 1.74 [0.91, 3.32]
3 Breathlessness - episodic after 48
hours
2 108 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.53, 1.09]
4 Breathlessness - episodic after 24
hours
2 116 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.71, 1.34]
Comparison 5. Secondary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects
(placebo-controlled)
4 66 Risk Difference (M-H, Random, 95% CI) 0.44 [-0.06, 0.94]
2 Adverse effects
(morphine-controlled)
2 194 Risk Difference (M-H, Random, 95% CI) -0.18 [-0.31, -0.04]
3 Adverse effects - clinical relevance
only (morphine-controlled)
2 54 Risk Difference (M-H, Random, 95% CI) -0.49 [-0.72, -0.25]
4 Adverse effects - drowsiness
and somnolence only
(placebo-controlled)
3 38 Risk Difference (M-H, Random, 95% CI) 0.74 [0.37, 1.11]
5 Adverse effects - drowsiness
and somnolence only
(morphine-controlled)
2 122 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.30, 0.16]
6 Attrition (placebo-controlled) 4 146 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.23, 0.05]
7 Attrition (morphine-controlled) 2 131 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.08, 0.08]
8 Deaths (placebo-controlled) 4 120 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.06, 0.05]
9 Deaths (morphine-controlled) 2 131 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.06, 0.06]
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Analysis 1.1. Comparison 1 Overall, Outcome 1 Placebo-controlled/cross-over design.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 1 Overall
Outcome: 1 Placebo-controlled/cross-over design
Study or subgroup Benzodiazepine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Harrison (unpublished) 17 44.49 (25.06) 17 45.94 (25.74) 22.1 % -0.06 [ -0.73, 0.62 ]
Man 1986 24 3 (0.8) 24 3 (0.8) 31.2 % 0.0 [ -0.57, 0.57 ]
Shivaram 1989 8 3.63 (1.92) 8 3 (1.6) 10.2 % 0.34 [ -0.65, 1.33 ]
Stege 2010 14 4.2 (2.9) 14 4.1 (2.5) 18.2 % 0.04 [ -0.71, 0.78 ]
Woodcock 1981 15 3.33 (1.11) 15 4.07 (0.88) 18.2 % -0.72 [ -1.46, 0.02 ]
Total (95% CI) 78 78 100.0 % -0.10 [ -0.42, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.69, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours benzodiazepine Favours placebo
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Analysis 1.2. Comparison 1 Overall, Outcome 2 Morphine-controlled/parallel design.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 1 Overall
Outcome: 2 Morphine-controlled/parallel design
Study or subgroup Benzodiazepine Morphine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Navigante 2006 (1) 23 3.1 (3.26) 24 2.8 (2.84) 50.0 % 0.10 [ -0.48, 0.67 ]
Navigante 2010 (2) 31 3.2 (1.95) 29 6 (1.83) 50.0 % -1.46 [ -2.03, -0.89 ]
Total (95% CI) 54 53 100.0 % -0.68 [ -2.21, 0.84 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 14.17, df = 1 (P = 0.00017); I2 =93%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
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Analysis 2.1. Comparison 2 Disease, Outcome 1 COPD.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 2 Disease
Outcome: 1 COPD
Study or subgroup Benzodiazepine Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Man 1986 24 3 (0.8) 24 3 (0.8) 36.8 % 0.0 [ -0.57, 0.57 ]
Shivaram 1989 8 3.63 (1.92) 8 3 (1.6) 14.8 % 0.34 [ -0.65, 1.33 ]
Stege 2010 14 4.2 (2.9) 14 4.1 (2.5) 24.2 % 0.04 [ -0.71, 0.78 ]
Woodcock 1981 15 3.33 (1.11) 15 4.07 (0.88) 24.2 % -0.72 [ -1.46, 0.02 ]
Total (95% CI) 61 61 100.0 % -0.12 [ -0.52, 0.29 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.67, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours benzodiazepine Favours placebo
Analysis 2.2. Comparison 2 Disease, Outcome 2 Cancer - placebo-controlled.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 2 Disease
Outcome: 2 Cancer - placebo-controlled
Study or subgroup Benzodiazepine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Harrison (unpublished) 17 44.49 (25.06) 17 45.94 (25.74) 100.0 % -0.06 [ -0.73, 0.62 ]
Total (95% CI) 17 17 100.0 % -0.06 [ -0.73, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours benzodiazepine Favours placebo
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Analysis 2.3. Comparison 2 Disease, Outcome 3 Cancer - morphine-controlled.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 2 Disease
Outcome: 3 Cancer - morphine-controlled
Study or subgroup Benzodiazepine Morphine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Navigante 2006 (1) 23 3.1 (3.26) 24 2.8 (2.84) 50.0 % 0.10 [ -0.48, 0.67 ]
Navigante 2010 (2) 31 3.2 (1.95) 29 6 (1.83) 50.0 % -1.46 [ -2.03, -0.89 ]
Total (95% CI) 54 53 100.0 % -0.68 [ -2.21, 0.84 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 14.17, df = 1 (P = 0.00017); I2 =93%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
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Analysis 3.1. Comparison 3 Intervention, Outcome 1 Benzodiazepines - alprazolam.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 1 Benzodiazepines - alprazolam
Study or subgroup Alprazolam Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Man 1986 24 3 (0.8) 24 3 (0.8) 75.3 % 0.0 [ -0.57, 0.57 ]
Shivaram 1989 8 3.63 (1.92) 8 3 (1.6) 24.7 % 0.34 [ -0.65, 1.33 ]
Total (95% CI) 32 32 100.0 % 0.08 [ -0.41, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours alprozolam Favours placebo
Analysis 3.2. Comparison 3 Intervention, Outcome 2 Benzodiazepines - diazepam.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 2 Benzodiazepines - diazepam
Study or subgroup Diazepam Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 1981 15 3.33 (1.11) 15 4.07 (0.88) 100.0 % -0.72 [ -1.46, 0.02 ]
Total (95% CI) 15 15 100.0 % -0.72 [ -1.46, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours diazepam Favours placebo
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Analysis 3.3. Comparison 3 Intervention, Outcome 3 Benzodiazepines - midazolam.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 3 Benzodiazepines - midazolam
Study or subgroup Midazolam Morphine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Navigante 2006 (1) 23 3.1 (3.26) 24 2.8 (2.84) 50.0 % 0.10 [ -0.48, 0.67 ]
Navigante 2010 (2) 31 3.2 (1.95) 29 6 (1.83) 50.0 % -1.46 [ -2.03, -0.89 ]
Total (95% CI) 54 53 100.0 % -0.68 [ -2.21, 0.84 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 14.17, df = 1 (P = 0.00017); I2 =93%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours midazolam Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
Analysis 3.4. Comparison 3 Intervention, Outcome 4 Benzodiazepines - temazepam.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 4 Benzodiazepines - temazepam
Study or subgroup Temazepam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stege 2010 14 4.2 (2.9) 14 4.1 (2.5) 100.0 % 0.10 [ -1.91, 2.11 ]
Total (95% CI) 14 14 100.0 % 0.10 [ -1.91, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours temazepam Favours placebo
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Analysis 3.5. Comparison 3 Intervention, Outcome 5 Benzodiazepines - ultra short-acting.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 5 Benzodiazepines - ultra short-acting
Study or subgroup ultra short-acting B. Morphine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Navigante 2006 (1) 23 3.1 (3.26) 24 2.8 (2.84) 50.0 % 0.10 [ -0.48, 0.67 ]
Navigante 2010 (2) 31 3.2 (1.95) 29 6 (1.83) 50.0 % -1.46 [ -2.03, -0.89 ]
Total (95% CI) 54 53 100.0 % -0.68 [ -2.21, 0.84 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 14.17, df = 1 (P = 0.00017); I2 =93%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours short-acting B. Favours morphine
(1) Assessment after 48 hours
(2) Assessment after five days.
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Analysis 3.6. Comparison 3 Intervention, Outcome 6 Benzodiazepines - intermediate-acting.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 6 Benzodiazepines - intermediate-acting
Study or subgroup Intermediate-acting B. Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Harrison (unpublished) 17 44.49 (25.06) 17 45.94 (25.74) 27.0 % -0.06 [ -0.73, 0.62 ]
Man 1986 24 3 (0.8) 24 3 (0.8) 38.2 % 0.0 [ -0.57, 0.57 ]
Shivaram 1989 8 3.63 (1.92) 8 3 (1.6) 12.5 % 0.34 [ -0.65, 1.33 ]
Stege 2010 14 4.2 (2.9) 14 4.1 (2.5) 22.3 % 0.04 [ -0.71, 0.78 ]
Total (95% CI) 63 63 100.0 % 0.04 [ -0.31, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Intermediate-acting B. Favours placebo
Analysis 3.7. Comparison 3 Intervention, Outcome 7 Benzodiazepines - long-acting.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 7 Benzodiazepines - long-acting
Study or subgroup Long-acting B. Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 1981 15 3.33 (1.11) 15 4.07 (0.88) 100.0 % -0.72 [ -1.46, 0.02 ]
Total (95% CI) 15 15 100.0 % -0.72 [ -1.46, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours long-acting B. Favours placebo
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Analysis 3.8. Comparison 3 Intervention, Outcome 8 Benzodiazepines - short duration of treatment (
<
= 24
hours).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 8 Benzodiazepines - short duration of treatment ( 24 hours)
Study or subgroup
Benzodiazepine
24 hours Morphine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Navigante 2006 (1) 26 4.1 (3.21) 29 3.9 (2.91) 49.3 % 0.06 [ -0.46, 0.59 ]
Navigante 2010 (2) 31 4.6 (2.45) 30 6.4 (2.08) 50.7 % -0.78 [ -1.30, -0.26 ]
Total (95% CI) 57 59 100.0 % -0.36 [ -0.74, 0.01 ]
Heterogeneity: Chi2 = 4.97, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Benzodiazepine 24 hours Favours morphine
(1) Assessment after 24 hours.
(2) Assessment at day two asking for breathlessness after 24 hours
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Analysis 3.9. Comparison 3 Intervention, Outcome 9 Benzodiazepines - long duration of treatment (5 to 14
days).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 9 Benzodiazepines - long duration of treatment (5 to 14 days)
Study or subgroup
Benzodiazepines
5-14 days Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Harrison (unpublished) 17 44.49 (25.06) 17 45.94 (25.74) 22.1 % -0.06 [ -0.73, 0.62 ]
Man 1986 24 3 (0.8) 24 3 (0.8) 31.2 % 0.0 [ -0.57, 0.57 ]
Shivaram 1989 8 3.63 (1.92) 8 3 (1.6) 10.2 % 0.34 [ -0.65, 1.33 ]
Stege 2010 14 4.2 (2.9) 14 4.1 (2.5) 18.2 % 0.04 [ -0.71, 0.78 ]
Woodcock 1981 15 3.33 (1.11) 15 4.07 (0.88) 18.2 % -0.72 [ -1.46, 0.02 ]
Total (95% CI) 78 78 100.0 % -0.10 [ -0.42, 0.21 ]
Heterogeneity: Chi2 = 3.69, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Benzodiazepines 5-14 days Favours placebo
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Analysis 3.10. Comparison 3 Intervention, Outcome 10 Benzodiazepines - morphine + midazolam-
controlled.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 10 Benzodiazepines - morphine + midazolam-controlled
Study or subgroup Midazolam Morphin+Midazolam
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Navigante 2006 (1) 23 3.1 (3.26) 23 3 (2.3) 100.0 % 0.03 [ -0.54, 0.61 ]
Total (95% CI) 23 23 100.0 % 0.03 [ -0.54, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours midazolam Favours morphin+midazolam
(1) Assessment after 48 hours.
Analysis 3.11. Comparison 3 Intervention, Outcome 11 Benzodiazepines - promethazine-controlled.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 3 Intervention
Outcome: 11 Benzodiazepines - promethazine-controlled
Study or subgroup Diazepam Promethazine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 1981 15 3.33 (1.11) 15 3.33 (0.62) 100.0 % 0.0 [ -0.72, 0.72 ]
Total (95% CI) 15 15 100.0 % 0.0 [ -0.72, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours diazepam Favours promethazine
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Analysis 4.1. Comparison 4 Primary outcome, Outcome 1 Breathlessness - no relief (placebo-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 4 Primary outcome
Outcome: 1 Breathlessness - no relief (placebo-controlled)
Study or subgroup Benzodiazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harrison (unpublished) 9/17 11/17 64.0 % 0.82 [ 0.46, 1.45 ]
Shivaram 1989 5/8 5/8 36.0 % 1.00 [ 0.47, 2.14 ]
Total (95% CI) 25 25 100.0 % 0.88 [ 0.56, 1.39 ]
Total events: 14 (Benzodiazepine), 16 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours benzodiazepine Favours placebo
Analysis 4.2. Comparison 4 Primary outcome, Outcome 2 Breathlessness - no relief (morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 4 Primary outcome
Outcome: 2 Breathlessness - no relief (morphine-controlled)
Study or subgroup Benzodiazepine Morphine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 14/26 9/29 100.0 % 1.74 [ 0.91, 3.32 ]
Total (95% CI) 26 29 100.0 % 1.74 [ 0.91, 3.32 ]
Total events: 14 (Benzodiazepine), 9 (Morphine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours benzodiazepine Favours morphine
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(1) Assessment after 48 hours.
Analysis 4.3. Comparison 4 Primary outcome, Outcome 3 Breathlessness - episodic after 48 hours.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 4 Primary outcome
Outcome: 3 Breathlessness - episodic after 48 hours
Study or subgroup Benzodiazepine Morphine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 10/23 11/24 31.5 % 0.95 [ 0.50, 1.79 ]
Navigante 2010 (2) 15/31 21/30 68.5 % 0.69 [ 0.45, 1.07 ]
Total (95% CI) 54 54 100.0 % 0.76 [ 0.53, 1.09 ]
Total events: 25 (Benzodiazepine), 32 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment at day three asking for breathlessness after 48 hours.
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Analysis 4.4. Comparison 4 Primary outcome, Outcome 4 Breathlessness - episodic after 24 hours.
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 4 Primary outcome
Outcome: 4 Breathlessness - episodic after 24 hours
Study or subgroup Benzodiazepine Morphine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 12/26 12/29 28.3 % 1.12 [ 0.61, 2.03 ]
Navigante 2010 (2) 19/31 20/30 71.7 % 0.92 [ 0.63, 1.34 ]
Total (95% CI) 57 59 100.0 % 0.97 [ 0.71, 1.34 ]
Total events: 31 (Benzodiazepine), 32 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours benzodiazepine Favours morphine
(1) Assessment after 24 hours.
(2) Assessment at day two asking for breathlessness after 24 hours
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Analysis 5.1. Comparison 5 Secondary outcomes, Outcome 1 Adverse effects (placebo-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 1 Adverse effects (placebo-controlled)
Study or subgroup Benzodiazepine Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harrison (unpublished) 5/9 4/9 22.7 % 0.11 [ -0.35, 0.57 ]
Man 1986 9/11 2/11 25.2 % 0.64 [ 0.31, 0.96 ]
Shivaram 1989 0/8 0/8 26.8 % 0.0 [ -0.21, 0.21 ]
Woodcock 1981 5/5 0/5 25.3 % 1.00 [ 0.69, 1.31 ]
Total (95% CI) 33 33 100.0 % 0.44 [ -0.06, 0.94 ]
Total events: 19 (Benzodiazepine), 6 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 31.37, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours benzodiazepine Favours placebo
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Analysis 5.2. Comparison 5 Secondary outcomes, Outcome 2 Adverse effects (morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 2 Adverse effects (morphine-controlled)
Study or subgroup Benzodiazepine Morphine
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 15/34 19/34 34.4 % -0.12 [ -0.35, 0.12 ]
Navigante 2010 (2) 25/63 38/63 65.6 % -0.21 [ -0.38, -0.04 ]
Total (95% CI) 97 97 100.0 % -0.18 [ -0.31, -0.04 ]
Total events: 40 (Benzodiazepine), 57 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
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Analysis 5.3. Comparison 5 Secondary outcomes, Outcome 3 Adverse effects - clinical relevance only
(morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 3 Adverse effects - clinical relevance only (morphine-controlled)
Study or subgroup Benzodiazepine Morphine
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 3/13 10/13 51.6 % -0.54 [ -0.86, -0.21 ]
Navigante 2010 (2) 4/14 10/14 48.4 % -0.43 [ -0.76, -0.09 ]
Total (95% CI) 27 27 100.0 % -0.49 [ -0.72, -0.25 ]
Total events: 7 (Benzodiazepine), 20 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000044)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Only follow-up phase
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Analysis 5.4. Comparison 5 Secondary outcomes, Outcome 4 Adverse effects - drowsiness and somnolence
only (placebo-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 4 Adverse effects - drowsiness and somnolence only (placebo-controlled)
Study or subgroup Benzodiazepine Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harrison (unpublished) 4/6 2/6 24.9 % 0.33 [ -0.20, 0.87 ]
Man 1986 7/8 1/8 37.2 % 0.75 [ 0.43, 1.07 ]
Woodcock 1981 5/5 0/5 37.9 % 1.00 [ 0.69, 1.31 ]
Total (95% CI) 19 19 100.0 % 0.74 [ 0.37, 1.11 ]
Total events: 16 (Benzodiazepine), 3 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.74, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 3.94 (P = 0.000082)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours benzodiazepine Favours placebo
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Analysis 5.5. Comparison 5 Secondary outcomes, Outcome 5 Adverse effects - drowsiness and somnolence
only (morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 5 Adverse effects - drowsiness and somnolence only (morphine-controlled)
Study or subgroup Benzodiazepine Morphine
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 7/18 11/18 37.7 % -0.22 [ -0.54, 0.10 ]
Navigante 2010 (2) 22/43 21/43 62.3 % 0.02 [ -0.19, 0.23 ]
Total (95% CI) 61 61 100.0 % -0.07 [ -0.30, 0.16 ]
Total events: 29 (Benzodiazepine), 32 (Morphine)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
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Analysis 5.6. Comparison 5 Secondary outcomes, Outcome 6 Attrition (placebo-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 6 Attrition (placebo-controlled)
Study or subgroup Benzodiazepine Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harrison (unpublished) 3/26 6/26 25.7 % -0.12 [ -0.32, 0.09 ]
Shivaram 1989 0/12 4/12 17.7 % -0.33 [ -0.61, -0.05 ]
Stege 2010 1/17 2/17 27.6 % -0.06 [ -0.25, 0.13 ]
Woodcock 1981 2/18 1/18 29.0 % 0.06 [ -0.12, 0.24 ]
Total (95% CI) 73 73 100.0 % -0.09 [ -0.23, 0.05 ]
Total events: 6 (Benzodiazepine), 13 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.70, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
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Analysis 5.7. Comparison 5 Secondary outcomes, Outcome 7 Attrition (morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 7 Attrition (morphine-controlled)
Study or subgroup Benzodiazepine Morphine
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 10/33 11/35 13.5 % -0.01 [ -0.23, 0.21 ]
Navigante 2010 (2) 1/32 1/31 86.5 % 0.00 [ -0.09, 0.09 ]
Total (95% CI) 65 66 100.0 % 0.00 [ -0.08, 0.08 ]
Total events: 11 (Benzodiazepine), 12 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
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Analysis 5.8. Comparison 5 Secondary outcomes, Outcome 8 Deaths (placebo-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 8 Deaths (placebo-controlled)
Study or subgroup Benzodiazepine Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harrison (unpublished) 0/13 2/13 6.5 % -0.15 [ -0.38, 0.07 ]
Man 1986 0/29 0/29 76.4 % 0.0 [ -0.06, 0.06 ]
Shivaram 1989 0/12 0/12 14.7 % 0.0 [ -0.15, 0.15 ]
Woodcock 1981 1/6 0/6 2.5 % 0.17 [ -0.19, 0.53 ]
Total (95% CI) 60 60 100.0 % -0.01 [ -0.06, 0.05 ]
Total events: 1 (Benzodiazepine), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.76, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours experimental Favours control
72Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.9. Comparison 5 Secondary outcomes, Outcome 9 Deaths (morphine-controlled).
Review: Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults
Comparison: 5 Secondary outcomes
Outcome: 9 Deaths (morphine-controlled)
Study or subgroup Benzodiazepine Morphine
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Navigante 2006 (1) 10/33 11/35 6.9 % -0.01 [ -0.23, 0.21 ]
Navigante 2010 (2) 0/32 0/31 93.1 % 0.0 [ -0.06, 0.06 ]
Total (95% CI) 65 66 100.0 % 0.00 [ -0.06, 0.06 ]
Total events: 10 (Benzodiazepine), 11 (Morphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours benzodiazepine Favours morphine
(1) Assessment after 48 hours.
(2) Assessment after five days.
A P P E N D I C E S
Appendix 1. Search strategies used for the original review
MEDLINE search strategy via OVID
1. exp dyspnea
2. dyspn$.mp.
3. breathing adj3 labour$
4. breathless$.mp.
5. shortness of breath.mp.
6. breathing difficult$.mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp benzodiazepines
9. benzodiazepine$.mp.
10. adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
11. 8 or 9 or 10
12. 7 AND 11
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EMBASE search strategy via OVID
1. exp DYSPNEA
2. dyspn$.mp.
3. breathing adj3 labour$
4. breathless$.mp.
5. shortness of breath.mp.
6. breathing difficult$.mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Benzodiazepine Derivative
9. benzodiazepine$.mp.
10. adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
11. 8 or 9 or 10
12. 7 AND 11
CINAHL search strategy via OVID
1. MH “dyspnea+”
2. dyspn*
3. breathing N3 labour*
4. breathless*
5. shortness of breath
6. breathing difficult*
7. 1 or 2 or 3 or 4 or 5 or 6
8. MH “Anxiety Agents, Benzodiazepine+”
9. benzodiazepine
10. adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
11. 8 or 9 or 10
12. 7 AND 11
PsycINFO search strategy via OVID
1. exp DYSPNEA
2. dyspn$.mp.
3. breathing adj3 labour$
4. breathless$.mp.
5. shortness of breath.mp.
6. breathing difficult$.mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp BENZODIAZEPINES
9. benzodiazepine$.mp.
10. adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
11. 8 or 9 or 10
12. 7 AND 11
CENTRAL search strategy
#1 MeSH descriptor Dyspnea explode all trees
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#2 dyspn*
#3 breathing adj3 labour*
#4 breathless*
#5 shortness of breath
#6 breathing difficult*
#7 1 or 2 or 3 or 4 or 5 or 6
#8 exp benzodiazepines
#9 benzodiazepine*
#10 adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
#11 8 or 9 or 10
#12 7 AND 11
PaPaS Register search strategy
((dyspn* or (breathing AND (laboured or labored)) or breathless* or “shortness of breath” or “breathing difficult*”) AND (benzodi-
azepines or adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam
or clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or diazepam or
estazolam or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or
ketazolam or loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam
or nitrazepam or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or
tofisopam or triazolam))
Search strategy for Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED via OVID
1. dyspn$.mp.
2. breathing adj3 labour$
3. breathless$.mp.
4. shortness of breath.mp.
5. breathing difficult$.mp.
6. 1 or 2 or 3 or 4 or 5
7. benzodiazepine$.mp.
8. adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or clon-
azepam or clorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or triazolam
9. 7 or 8
10. 6 AND 9
Search strategy for Iowa Drug Information System (IDIS) and International Pharmaceutical Abstracts
((benzodiazepines or tetrazepam or diazepam or oxatepam or lorazepam or lormetazepam or clotiazepam or pinazepam or uldazepam
or quazepam or temazepam or metaclazepam nordazepam or fludiazepam or flunitrazepam or halazepam or clonazepam or nitrazepam
or zolazepam or flurazepam or flutoprazepam or prazepam or clazepam or meclonazepam or fosazepam or midazolam or medazepam
or clotiazepam or doxefazepam or premazepam or camazepam or ritazepam or delorazepam or bentazepam or bromazepam) AND
((abnormality, resp & dyspnea) or (apnea, unspecified)))
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Appendix 2. Search strategy for the review update 2016
MEDLINE search strategy via OVID (update)
1. exp dyspnea/
2. dyspn$.mp.
3. (breathing adj3 labo?r$).mp.
4. breathless$.mp.
5. (short* adj2 breath).mp.
6. breathing difficult$.mp.
7. or/1-6
8. exp benzodiazepines/
9. benzodiazepine$.mp.
10. (adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or
triazolam).mp.
11. or/8-10
12. 7 and 11
13. (200909* or 200910* or 200911* or 200912* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016*).ed.
14. 12 and 13
EMBASE search via OVID (update)
1. exp dyspnea/
2. dyspn$.mp.
3. (breathing adj3 labo?r$).mp.
4. breathless$.mp.
5. (short* adj2 breath).mp.
6. breathing difficult$.mp.
7. or/1-6
8. exp Benzodiazepine Derivative/
9. benzodiazepine$.mp.
10. (adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or
triazolam).mp.
11. or/8-10
12. 7 and 11
13. (200909* or 200910* or 200911* or 200912* or 2010* or 2011* or 2012* or 2013* or 2014 or 2015* or 2016*).dd
14. 12 and 13
CENTRAL search strategy via the Cochrane Library (update)
#1 MeSH descriptor: [Dyspnea] explode all trees
#2 dyspn*:ti,ab,kw (Word variations have been searched)
#3 (breathing near/3 labo?r*):ti,ab,kw (Word variations have been searched)
#4 breathless*:ti,ab,kw (Word variations have been searched)
#5 (short* near/2 breath):ti,ab,kw (Word variations have been searched)
#6 breathing difficult*:ti,ab,kw (Word variations have been searched)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Benzodiazepines] explode all trees
#9 benzodiazepine*:ti,ab,kw (Word variations have been searched)
76Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#10 (adinazolam or alprazolam or bentazepam or bromazepam or brotizolam or chlordiazepoxide or cinolazepam or clobazam or
clonazepam or clorazepate or clotiazepam or cloxazolam or delorazepamor demoxepam or desmethyldiazepam or diazepam or estazolam
or etizolam or etozolam or fludiazepam or flunitrazepam or flurazepam or flutoprazepam or halazepam or haloxazolam or ketazolam or
loprazolam or lorazepam or lormetazepam or medazepam or metaclazepam or mexazolam or midazolam or nimetazepam or nitrazepam
or nordazepam or oxazepam or oxazolam or pinazepam or prazepam or quazepam or temazepam or tetrazepam or tofisopam or
triazolam):ti,ab,kw (Word variations have been searched)
#11 #8 or #9 or #10
WH A T ’ S N E W
Last assessed as up-to-date: 23 August 2016.
Date Event Description
21 October 2016 Review declared as stable See Published notes.
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 1, 2010
Date Event Description
15 September 2016 New citation required but conclusions have not
changed
We included one new study in the update, but the
conclusion did not change. We identified two studies
awaiting assessment
29 August 2016 New search has been performed We updated this review to include the results of new
search (August 2016). We have added new ’Risk of
bias’ summary tables and updated contact details
6 October 2010 Amended We have updated contact details.
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to the development of the idea for this review, revised the manuscript, and approved the final version.
STS: developed and wrote the protocol, developed the search strategies and the data extraction form, searched for studies, obtained
copies of the studies, extracted data from studies, entered data into RevMan, carried out analysis and meta-analysis, drafted the review
and finalised it after discussion with the other review authors. Responsible for further updates.
IJH: discussed and approved the protocol, the search strategy, and the data extraction form, discussed the outcomes and analysis with
the other review authors, and provided epidemiological and wider systematic review expertise.
SB: discussed and approved the protocol, the search strategy, and the data extraction form, checked extracted information from studies,
discussed the outcomes and analysis with the other review authors.
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RH: discussed and approved the protocol, the search strategy, and the data extraction form, discussed the outcomes and analysis with
the other review authors, and provided social science expertise.
VW: searched for studies for the update, extracted data from studies for the update, entered data intoRevMan for the update, contributed
to the meta-analysis for the update, drafted the review update.
CB: supervised the protocol, contributed to the development of the search strategy and the data extraction form, searched the titles,
extracted data from studies, supervised the analysis, discussed the outcomes and analysis with the other review authors, and provided
wider systematic review expertise.
D E C L A R A T I O N S O F I N T E R E S T
STS: none known. STS is a specialist in palliative care and works as a physician caring for patients with life-limiting diseases.
IJH: none known. IJH is a specialist in palliative care and works as a researcher and physician caring for patients with life-limiting
diseases.
SB: none known. SB worked as a specialist in palliative care and and now supports patients with chronic illness.
RH: none known. RH is a reader in palliative care and works as a researcher in palliative care with focus on HIV/AIDS, Sub-Saharan
Africa and Global Health.
VW received reimbursement of travel costs from Teva Pharmaceutical Industries Ltd. for the 8th World Research Congress of the
European Association of Palliative Care (Lleida, Spain, 2014) outside the submitted work. VW is a health economist with experience
in research in palliative care (2011-2015) and works as a research associate at an institute of quality and efficiency in health care (since
2015).
CB: none known. CB is a specialist in palliative care and works as a physician caring for patients with life-limiting diseases.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Palliative Care, Policy and Rehabilitation, King’s College London, UK.
• Institute of Palliative Care, Germany.
• Department of Palliative Medicine, University Hospital of Cologne, Germany.
External sources
• The Werner Jackstaedt Foundation, Germany.
• The Federal Ministry of Education and Research (BMBF; 01KG1509), Germany.
Research grant for the conduction of the review update (2015)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the previous version of the review, we changed the title slightly by inserting ’advanced’ in front of ’malignant’. This resulted in no
changes to the included and excluded studies.
N O T E S
A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore,
this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new
evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Benzodiazepines [∗therapeutic use]; Dyspnea [∗drug therapy; etiology]; LungNeoplasms [∗complications]; PulmonaryDisease, Chronic
Obstructive [∗complications]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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